Curcumin Formulations for Better Bioavailability: What We Learned from Clinical Trials Thus Far?

Introduction

Chronic diseases including autoimmune diseases, cancer, cardiovascular diseases, diabetes, hepatocellular, neurological, and renal diseases have persistent high incidence and fatality rates worldwide. 1 , 2 Finding feasible treatment strategies are challenging due to the high prevalence of these diseases and the involvement of several pathways in their development, including JAK/STAT3, JNK, NF-κB, MEK/ERK, p38/MAPK, and PI3K/Akt/mTOR, etc. 1 − 10 Therefore, classical monotarget therapies are insufficient to treat these diseases. Besides, the cost of contemporary pharmaceuticals is high, and have several unfavorable side effects. 7 , 10 , 11 Indeed, there is an increasing need for the development of safer, effective, multitargeted, and cost-effective therapeutic regimens to replace the current harmful and ineffective treatment approaches. A growing body of preclinical and clinical evidence suggests that natural substances derived from diverse plants are potential therapeutic candidates against a wide range of fatal chronic conditions, and their alternative formulations can be employed to boost the bioavailabilities of these substances. 2 , 7 , 10 , 12 − 14

The perennial herb turmeric, Curcuma longa Linn. belongs to the Zingiberaceae family, is indigenous to South Asia’s tropical areas. The rhizomes of this plant have been used for centuries as a remedy for several diseases in the Indian (Ayurveda) and Chinese Medicinal Systems. 15 − 17 Curcumin is a bioactive phytochemical derived from this rhizome. It has traditionally been used as a spice, food preservative, and coloring ingredient. 15 , 18 The chemical name for curcumin is diferuloylmethane (C 21 H 20 O 6 ) and the IUPAC name is (1 E -6 E )-1,7-bis(4-hydroxy-3-methoxy phenyl)-1,6-heptadiene-3,5-dione with a molecular weight of 368.37 g/mol and melting point of 183 °C. The two aryl rings in curcumin are symmetrically connected to a β-diketone moiety by ortho-methoxy phenolic groups. 17 − 21 A pH-dependent keto-enol tautomerism appears in curcumin wherein the stable enol form predominates in an alkaline medium and a keto form in acidic and neutral conditions. 17 In addition, curcumin’s color varies depending on the pH level, yielding a brilliant yellow solution between 2.5 and 7.0, and turning to dark red when the pH rises over that level. 17 , 20

Currently, there are several curcumin-based products available in the market, including pills, ointments, capsules, and cosmetics. 16 , 22 − 24 Turmeric and curcumin have been the established remedies for various ailments, primarily as antiatherosclerotic, antibacterial, anticancerous, antifungal, anti-inflammatory, antioxidant, antithrombotic, and antiviral agents. 22 , 25 , 26 Additionally, a comprehensive analysis of the literature identified curcumin as one of the excellent natural compounds that exhibit analgesic, antirheumatic effects, hypoglycemia, hypolipidemia, hepatoprotective, nephron protective, pulmonoprotective, and cardioprotective activities. 18 , 21 , 27 − 35 Besides, in vitro studies have shown that curcumin modulates several cell signaling pathways, upregulates p53, p21, and p27, downregulates cell survival gene products, and induces apoptosis. 15 , 36 − 39 Numerous clinical studies have demonstrated its outstanding safety, tolerability, and effectiveness even at higher oral dosages, and is currently being sold as a dietary supplement in several countries across the world. 27 , 28 , 40 , 41 Curcumin has not yet been authorized as a drug despite its excellent efficacy and safety, and a key issue for this is the relative bioavailability of curcumin. Research over the last three decades has revealed the poor gut absorption, rapid metabolism, and systemic elimination of curcumin that significantly restricts its bioavailability. 18 , 23 , 42 − 44 Moreover, curcumin is a hydrophobic molecule with a log P of ∼3.2 (octanol-water partition coefficient), making it practically water-insoluble (with a water solubility of only 30 nM). 21 , 45 − 47 Curcumin activity has a reported half-life of 10 min in a phosphate buffer of pH 7.4 which further limits its clinical use. 46 , 47 Even after consuming high amounts of conventional curcumin, very low levels of plasma curcumin were detected. Hence, the overarching goal of all strategies is to increase curcumin’s solubility and bioavailability. 48 − 52 Numerous approaches have been used to improve the solubility and subsequently the bioavailability of curcumin including curcumin-piperine complex, curcumin nanoparticles or nanomicelles, liposomal curcumin, phospholipidated curcumin, and phytosomal curcumin complex. 18 , 42 , 44 , 47 , 53 , 54 Therefore, in the current review, we provide an overview of the bioavailability, safety, tolerability, and efficacy of various curcumin formulations in clinical trials. We have extensively reviewed the completed clinical trials on curcumin formulations of different generations and highlighted their efficacy in treating several chronic diseases. Significant variations in research design, volunteer race, dose, duration, and route of administration were noted. Moreover, we discussed the advantages and limitations of these formulations and highlighted the future perspectives from the podium to clinical practice.

Bioavailability of Conventional Curcumin

The major findings from curcumin research are the observation of noticeably low serum levels, limited tissue distribution, rapid metabolism, inactive metabolite formation, and rapid clearance/elimination from the body. 18 , 42 , 47 , 48 , 55 Several studies have shown that administration of a large amount of pure curcumin yielded only a trace amount of serum levels of curcumin in rats owing to its poor absorption from the gut. 55 − 60 Curcumin administered orally at 2 g/kg to rats showed a maximum serum concentration of only 1.35 ± 0.23 μg/mL at 0.83 h, whereas the same dosage showed undetectable or extremely low serum levels, i.e., 0.006 ± 0.005 μg/mL at 1 h. 55 Similarly, in another clinical trial, it was shown that administration of 3.6 g of curcumin by the oral route generated serum levels of only 11.1 nmol/L after 1 h. 51 More recently, Yang and colleagues demonstrated that curcumin given intravenously (10 mg/kg) produced a maximum serum level of 0.36 ± 0.05 g/mL, whereas a 50-fold increase in dosage of oral supplement produced only a maximum serum level of 0.06 ± 0.01 g/mL in rats. 56 Besides, following oral treatment of 400 mg of curcumin in rats, Ravindranath et al. demonstrated that only residues of the unmodified substance were discovered in the liver and kidney. 59 This study also showed that 90% of curcumin was noted in the stomach and small intestine at 30 min while only 1% of curcumin was present after 24 h. 59 Another study revealed that administration of radiolabeled (tritium or H 3 ) curcumin at 10, 80, and 400 mg doses resulted in the detection of a considerable amount of curcumin in tissues of rats administered with only 400 mg after 12 days. 58 Also, the percentage of absorbed curcumin remained constant irrespective of the dosage indicating the dose-independent limitations to bioavailability in these animals. 58 Similarly, supplementation of 450–3600 mg of curcumin daily for a week before surgery to patients with colorectal cancer metastases to liver showed no curcumin in their liver tissues. 61 In phase II clinical trial on patients with advanced pancreatic cancer, an oral dose of 8 g/day curcumin resulted in only 22–41 ng/mL of plasma concentration. 62 Further, orally given curcumin (2 g/kg) to rats had an absorption half-life of 0.31 ± 0.07 and elimination half-life of 1.7 ± 0.58 h, albeit in humans, the same dose did not enable the measurement of these shelf life values since most of the levels were below the detection limit at almost all the periods. 55

These studies indicated that the method of administration (whether oral or intravenous) affects the serum levels of curcumin and further suggest that the serum achievable concentrations of curcumin in humans and rats are not exactly comparable. Hence, it is not only imperative to develop bioavailable curcumin but also equally important to find the safety and efficacy of these formulations in humans.

Methodology

A literature search was carried out using “curcumin and clinical trials” in two different databases, Pubmed and Scopus, until June 2022. Around 458 articles appeared in PubMed and 3622 articles appeared in Scopus for the mentioned keyword. The studies that appeared were analyzed thoroughly for the mentioned keywords.

The inclusion criteria applied to select the relevant studies were (a) clinical studies that have used various generations of curcumin formulation; (b) studies on human subjects (both healthy and diseased); (c) full-text manuscripts in English. The exclusion criteria were (a) preclinical studies; (b) studies on the pure form of curcumin; (c) full-text not in English; (d) in silico studies; (e) conference abstracts; (f) review articles; (g) meta-analysis; and (h) case reports. All the relevant articles as per these criteria are included in the table, figures, and text.

Curcumin Formulations

The straightforward ways to address the limitation(s) of curcumin are to enhance its bioavailability, shield it from oxidation and metabolism, and increase its ability to target diseased tissues and/or organs. 18 , 47 One of the main strategies for increasing curcumin’s bioavailability is to utilize adjuvants that can inhibit or delay its metabolism. 18 , 63 Other intriguing innovative formulations that appear to offer longer circulation, improved permeability, and resistance to metabolic processes include liposomes, micelles, nanoparticles, and phospholipid complexes. 18 , 42 , 64 These bioavailable or bioenhanced formulations of curcumin are generally categorized into three different formulations. The classic example of first-generation formulation includes the use of significant amounts of adjuvants such as piperine from black pepper, turmeric oils, or any other natural compounds that were included to inhibit the essential detoxification enzymes such as hepatic aryl hydrocarbon hydroxylase, cytochrome P450, mixed-function oxygenases, and UDP-glucuronyltransferase. 18 , 63 , 65 , 66 The first-generation formulation enhances the absorption time of curcumin by inhibiting or delaying its metabolism. The formulations such as curcumin–piperine, C3 complex–piperine (C3 complex/bioperine), turmeric fiber or oil with curcumin, BCM-95, and Cureit belong to the first-generation category. 44 In the second-generation, emulsifiers such as carbohydrate complexes, polyethoxylated hydrogenated castor oil, lipid complexes, phospholipid complexes, polysorbates, water-dispersible nanopreparations, and spray drying were used to increase the solubility of curcumin. These included BioCurc, Cavacurcmin, CurcuWIN, Hydrocurc, Meriva, Nanocurcumin, Novasol, Theracurmin, and Turmipure Gold. 44 Although increases in plasma curcuminoids levels occur primarily through their conjugated metabolites (glucuronides and sulfates), numerous studies have shown that these conjugated metabolites lack biologically significant effects because of the large size, quick renal elimination, limited membrane, and blood–brain barrier (BBB) permeability. 44 , 67 , 68 For this reason, delivering curcumin in its free form (naturally unconjugated) is essential to maximize its therapeutic effects. The third-generation curcumin formulations including Longvida and CurQfen have solved the issue of “free” curcuminoids bioavailability, membrane permeability, and cellular uptake without the use of artificial emulsifiers like polysorbates. 44 This section details the clinical safety and efficacy of all three generations of curcumin formulations. Different formulations and their composition are listed in Table 1 .

First-generation curcumin formulation

Early attempts to increase absorption of curcumin included the addition of turmeric oil (BCM-95; BioCurcumax; Curcugreen), a small amount of piperine (curcumin C3 complex) to stimulate the gastrointestinal system, prevent curcumin efflux and inhibit hepatic and intestinal glucuronidation, or as a turmeric oleoresin (Curcugen). 18 , 44 , 55 All of these formulations have shown incremental improvement in curcumin absorption and efficacy clinically ( Table 2 , Figure 1 ). For instance, supplementation with curcumin/piperine (500 mg-2g/day curcumin plus 5–20 mg/day piperine) formulation resulted in a significant reduction in ubiquitin, muscle atrophy F box (MAFbx)/atrogin-1, chymotrypsin-like protease, interleukin 2 (IL-2), TNF-α, INF, IL-6, IL-10, and enhancement in bioavailability, safety, tolerability, and delayed onset of muscle soreness in healthy subjects without adverse side effects. 55 , 69 , 70

In patients with arsenic-induced oxidative stress, this formulation effectively decreased DNA damage, ROS generation, lipid peroxidation, and improved antioxidant capacity. 71 In another study, the administration of curcumin (1.5 mg/day) and piperine (5 mg/day) for 2 months resulted in the efficient alleviation of IL-6 and improvement in forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and asthma control test scores in bronchial asthma patients compared to those who received regular asthma drugs. 72 Moreover, this formulation (1–1.5 g/day curcumin with 5 mg/day piperine) reduced the symptoms including weakness, dry cough, sore throat, sputum cough, ague muscular pain, headache, dyspnea, deterioration, and hospitalized duration in COVID-19 patients without side effects. 73 , 74 Besides, the treatment with this formulation significantly improved mouth opening flexibility, cheek flexibility, and tongue protrusion capacity and suppressed burning sensation in oral submucous fibrosis (OSF) patients compared to placebo (starch and lactose capsules). 75 In another randomized placebo-controlled trial, this formulation was shown to effectively augment GSH levels and decrease erythrocyte MDA levels in pancreatitis patients with no adverse side effects. 76 In addition, it also reduced leptin and TNF-α levels and increased adiponectin levels in T2D patients over 12 weeks of treatment. 77 Curcumin formulation with piperine and ginger ameliorated erythrocyte sedimentation rate (ESR), tender joint count (TJC), swelling joint count (SJC), disease activity score (DAS), and relieved pain and inflammation in rheumatoid arthritis patients. 78 Another study demonstrated that curcumin along with piperine and taurine remarkably suppressed IL-10, AST, ALT, α-L-fucosidase, and miR-21 levels and improved overall survival in hepatocellular cancer patients. 79 Another curcumin/piperine tablet containing other ingredients including propranolol, aliskiren, cilazapril, celecoxib, aspirin, and metformin for 10 weeks enhanced the median survival rate in glioblastoma patients. 80 This treatment was also found to be safe with minimal side effects including indigestion and marginal bradycardia (propranolol effect). 80 Another study employed two tablets of curcumin–spirulina– Boswellia extract (each tablet with 400 mg curcumin, 50 mg spirulina, and 50 mg Boswellia extract) to patients with benign thyroid nodules and reported the reduced nodule area without adverse side events. 81 Also, curcumin and fennel essential oil (FEO) tablets (2 capsules, a total of 84 mg curcumin with 50 mg FEO) caused substantial relief in symptoms and improved quality of life in inflammatory bowel syndrome (IBS) patients. 82 Moreover, the administration of three Oxy-Q tablets (each tablet containing 480 mg curcumin with 20 mg quercetin) repressed polyp size and number without side effects in familial adenomatous polyposis patients (FAP). 83 In another study, a novel curcumin formulation administered as 2 capsules per day (each capsule containing 30 mg curcumin, 100 mg bovine lactoferrin, 15 mg zinc acetate, 100 mg lysolecithin), 600 mg N -acetylcysteine (NAC), and 20 mg pantoprazole inhibited serum pepsinogens, decreased disease severity and improved the cure rate in patients infected with Helicobacter pylori ( H. pylori ). 84 In addition, rectal suppositories of 350 mg curcumin and 80 mg Calendula extract (1 suppository/die, for 1 month) significantly inhibited inflammation compared to those who received a placebo suppository (identical to treatment) without side effects. 85 Yet another formulation, Curcumin Forte (95% curcumin plus 5% piperine formulation) remarkably increased positive and negative symptoms scale (PANSS) and reduced Calgary depression scale for schizophrenia (CDSS) scores in schizophrenic patients with no reported adverse side effects compared to identical colored and sized placebo tablets. 86 Further, washing the mouth with curcumin and chitosan solution (10 mL) three times a day for 2 weeks inhibited Candida activity and achieved a complete response in 80% of denture stomatitis patients. 87 In another study mouthwash containing essential oils and curcumin (MEC) effectively reduced ESR, rheumatoid factor (RF), CRP, anticitrullinated peptide antibody (ACPA), plaque index (PI), pocket depth (PD), clinical attachment level (CAL) and also was found to be well-tolerated in rheumatoid arthritis (RA) patients with periodontitis. 88

C3 complex/bioperine, a curcuminoid extract containing curcumin, desmethoxycurcumin, and bisdemethoxycurcumin in combination with bioperine (piperine), has been demonstrated to be anti-inflammatory, antidiabetic, and antiarthritic agent. 89 − 91 C3 complex/bioperine administered at the dose of 500 mg to 12 g per day for the duration of 7 days to months was safe, tolerated, and effective without any serious side effects. 40 , 89 , 90 , 92 − 104 Moreover, randomized clinical trials have shown that administration of C3 complex/bioperine (1 g/day of C3 complex plus 10 mg/day of bioperine) in patients with metabolic syndrome effectively reduced C-reactive protein (CRP), glucose, glycated hemoglobin (HbA1c), lipoprotein a (LPA), low-density lipoprotein cholesterol (LDL-C), nonhigh-density lipoprotein cholesterol (non-HDL-C), malondialdehyde (MDA), total cholesterol (TC), triglycerides (TG), systolic blood pressure (SBP), diastolic blood pressure (DBP), interleukin 6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), leptin, tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β), and upregulated adiponectin, HDL-C, and superoxide dismutase (SOD) levels compared to placebo containing the same amount of lactose and bioperine in a matched shape, size and color. 92 − 95 The treatment with this formulation was also shown to improve nonalcoholic fatty liver disease (NAFLD) by decreasing alanine aminotransferase (ALT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), hematocrit, erythrocyte sedimentation rate (ESR), iron, hemoglobin (Hb), LDL-C, TC, MCP-1, TNF-α, and epidermal growth factor (EGF). 96 , 97 Besides, C3 complex/bioperine formulation remarkably reduced TG, interleukin 1 beta (IL-1β), interleukin 4 (IL-4), PAB and vascular endothelial growth factor (VEGF), and enhanced zinc/copper (Zn/Cu) ratio in obese subjects. 98 , 105 − 107 In addition, in randomized double-blind clinical trials, oral intake of this formulation (1.5 g/day) for 6 weeks was shown to reduce MDA and oxidative stress levels and upregulated SOD and glutathione (GSH) levels in osteoarthritis patients. 91 , 108 Interestingly, in clinical trials administration of C3 complex (1–1.5 g/day) with bioperine (10–15 mg/day) for 4 weeks showed increased levels of glutathione peroxidase (GPx), SOD, catalase (CAT), and decreased levels of substance P (Sp), visual analog scale (VAS), pruritus severity, dermatology life quality index (DLQI) scores, interleukin 8 (IL-8), high sensitivity CRP (hs-CRP), calcitonin-gene related peptide (CGRP), FEV1, FVC, IL-6, TNF-α, TGF-β, MCP-1, St. George respiratory questionnaire (SGRQ) score and increased glutathione and COPD assessment test (CpAT) scores in patients with sulfur-mustard induced chronic pruritis and pulmonary complications. 89 , 99 , 109 , 110 Ingestion of this complex also showed antidiabetic effects by reducing glucose, C-peptide, HbA1c, ALT, Non-HDL-C, LPA, MDA, and AST and increasing total antioxidant capacity (TAC) and SOD levels in diabetic patients. 90 , 104 , 111 Further, this regimen showed a promising effect in treating critically ill traumatic brain injury (TBI) patients by increasing GPx levels and suppressing leptin, IL-6, CRP, MCP-1, TNF-α, acute physiology, and chronic health evaluation II (APACHE II) score, sequential organ failure assessment (SOFA) score, and nutrition risk in critically ill (NUTRIC) score. 100 , 101 It was also shown to be effective in treating premenstrual syndrome (PMS) and dysmenorrhea with a remarkable reduction in AST, direct bilirubin, dysmenorrhea pain, and PMS screening tool (PSST) score and enhancement in vitamin D levels. 102 , 103 This C3 and piperine formulation, however, showed no significant effect on pro-oxidant antioxidant balance (PAB) in NAFLD patients after 8 weeks treatment. 112 Moreover, turmix tablet (300 mg curcumin plus 5 mg piperine) with or without turmix mouthwash for 12 weeks reduced burning sensation, improved mouth opening capacity, and tongue protruding ability in OSF patients. 113 , 114 However, this combination was shown to provide no effects on paracetamol metabolization in healthy subjects. 115

BCM-95 is a novel well established curcumin formulation wherein curcumin is complexed with essential oils from turmeric rhizome, rice flour, vegetable cellulose, vegetable stearate, and silica. 116 BCM-95 has been shown to provide improved bioavailability and increased retention time of curcumin compared to curcumin-lecithin and curcumin-piperine formulations in healthy subjects. 117 Several clinical trials have proven the safety, tolerability, and efficacy of BCM-95 in humans. 117 − 121 BCM-95 is effective in treating multiple myeloma, multiple sclerosis, NAFLD, and prediabetic conditions by reducing BMI, weight, TC, TG, low-density lipoprotein (LDL), inflammatory molecules such as NF-κB, IL-6, TNF-α, and VEGF, liver enzymes including AST and ALT, diseases lesions, and hepatic fibrosis. 118 − 121 BCM-95 treatment increased high-density lipoprotein (HDL), overall remission rate, and physical activity in these patients. 118 − 121 In another study, oral intake of an active natural ingredient formulation (A total of 830 mg formulation consisting of fish oil 250 mg, phosphatidyl choline concentrated sunflower oil 150 mg, silymarin 75 mg, choline bitartrate 35 mg, curcumin 35 mg, D-α-tocopherol 10 mg) capsules (2 capsules/day) for 3 months was shown to be effective in decreasing liver enzymes such as AST, in patients with NAFLD compared to those who received tablet containing the same amount of choline and formulation excipients. 122 This shows that efficacy is attributed to curcumin but not to choline and hence, the anti-NAFLD effect is a stand-alone effect of administered first-generation curcumin formulation. 122 Although, ALT, and gamma-glutamyl transferase (GGT) levels were decreased in these patients after curcumin treatment the reduction was not found to be statistically significant. This formulation has also been shown to be safe and well-tolerated with no reported adverse side effects. 122 It was also shown that administration of another dietary supplement product CartiJoint Forte, a formulation of BCM-95, chondroitin sulfate, and glucosamine hydrochloride, resulted in a significant reduction in VAS score and WOMAC score in osteoarthritis patients with no noticeable adverse events compared to placebo group. 123 Another two novel BCM-95 formulations, CuraMed (552–578 mg of BCM-95 extracted in ethanol 99% (v/v) and 100% ethyl acetate, 49–52 mg volatile oil from C. longa containing 22–23.4 mg aromatic turmerone, and inactive excipients) and CuraMin (350 mg BCM-95, 150 mg of Boswellia serrata Roxb. ex Colebr gum resin extract corresponding to 75% boswellic acids and 10% 3- O -acetyl-11-keto-boswellic acid) have been demonstrated to ameliorate the pain, stiffness, degree of difficulty in moving the knee joint, and to enhance the physical performance in osteoarthritis patients. The placebo used in this study contained calcium phosphate, FD&C yellow 5, FD&C yellow 6, gelatin, magnesium stearate, maltodextrin, silica oxide, and titanium oxide. Both the formulations were found to be safe, well-tolerated, and did not show any serious adverse side effects on these patients. 124 Moreover, CuraMed also reduced postoperative discomfort and pain in periodontitis patients compared to control group who received mefenamic acid. 125 In another study, Curcugreen (dry turmeric rhizomes extracted with ethyl acetate called turmeric oleoresin, precipitated and combined with turmeric essential oil) alone or in combination with zinc was found to be effective in treating obesity by reducing body mass index (BMI), fasting plasma glucose (FPG), HbA1c, insulin, insulin resistance and increasing physical performance capacity compared to zinc with lactose as placebo tablets. 126 Besides, oral spray formulation of curcumin, ArtemiC containing 12 mg artemisinin, 40 mg curcumin, 30 mg frankincense, and 120 mg vitamin C in 1 mL spray when used twice a day for 2 days enhanced the clinical improvement, oxygen saturation and decreased fever and hospitalized duration in coronavirus disease 19 (COVID-19) patients compared to placebo spray (containing the same solvent of ArtemiC except for the active ingredients). 127 No reported adverse effects were observed in this trial. 127 Moreover, curcumin bioactive capsules containing 500 mg/day rutin, 1.5 g/day fish oil (18% EPA and 7% DHA), 50 mg/day curcumin (95% curcuminoids) along with 20 g whey protein isolate (WPI) for 12 weeks has been shown to ameliorate age-related sarcopenia as evidenced by enhanced gait speed and knee extension strength without any serious side effects. 128 In another study, CUC-1 formulation (curcumin with paclitaxel) administered intravenously (300 mg solution/week) increased physical performance and objective responsive rate (ORR) in metastatic breast cancer patients (MBC) (n = 150). 129 However, this intravenous infusion resulted in anemia and hematological grade 3–5 side effects in a few patients (n = 5). 129 Oral intake of two Coltect tablets (each tablet containing 500 mg curcumin, 250 mg green tea, and 100 μg selenium) per day for 8 weeks enhanced the remission rate and suppressed the clinical activity of ulcers in ulcerative colitis patients. 130 This formulation was also found to be safe and well-tolerated among these patients. 130

Another formulation, Curcumall (curcumin C3 95%, turmeric, and ginger dissolved in glycerin and 0.4% alcohol) was shown to have no adverse effects on patients with oral lichen planus (OLP). 131 Additionally, curcumin dispersion amorphous formulation (500 mg/day) was reported to significantly reduce LDL-C, TG, AST, ALT, glucose, and HbA1c, and was safe, well-tolerated, and had no side effects in NAFLD patients. 132 Another study showed that curcumin capsules (Theravalues Co. Tokyo, Japan) containing 0.27% citric acid, 10% Curcumin, 2% other curcuminoids, 54.53% dextrin, 3.2% gum ghatti, and 30% maltose enhanced biological antioxidant potential (BAP), GSH and CAT and suppressed derivatives of reactive oxygen metabolites in healthy subjects with exercise-induced oxidative stress. 133 In addition, the novel curcumin formulation, Cureit/Acumin (46.5% total curcuminoids, 43% total carbohydrates, 5% fiber, 2.4% proteins, 3.2% volatile oil) exhibited enhanced bioavailability than phospholipid and volatile oil formulation of curcumin and was found to be safe without any side effects and improved handgrip strength, weight lifting capacity, walking distance and reduced the creatinine kinase (CK), muscle soreness and time taken to walk the same distance in healthy volunteers. 134 − 136 Another randomized study tested the effectiveness of curcumin essential oil formulation, curcumin phytosomal formulation, and γ-cyclodextrin curcumin formulation on healthy volunteers and reported enhanced curcumin absorption without adverse events. 137 Furthermore, curcuminoid turmeric matrix formulation (50% total curcuminoids, 3% essential oil, 2% protein, 40% total carbohydrate) suppressed CRP, rheumatoid factor (RF), SJC, TJC, ESR, and disease activity scores compared with food-grade starch as placebo in RA patients. 138 In another study, curcumin turmeric oil formulation (440 mg curcuminoid, 38 mg of turmeric oil) reduced mean weight, BMI, waist circumference, FBS, TG, hs-CRP, and increased adiponectin levels in T2D patients compared to administration of the same amount of rice flour as placebo. 139 , 140 Heng and colleagues showed that the application of curcumin alcohol gel reduced phosphorylase kinase activity, TRR, the severity of parakeratosis, and CD8+ T cells in psoriasis patients. 141 Similarly, the application of curcumin gel or curcumin mucoadhesive patch formulation reduced the burning sensation and improved mouth opening capacity in patients with OSF without any adverse side effects. 142 , 143

Another novel curcumin formulation, Infla-Kine containing a proprietary blend of Lactobacillus fermentum extract, lipoic acid, burdock seed, papaya enzyme, zinc, and BCM-95 downregulated inflammatory cytokines such as IL-6, IL-8, NF-κB, and TNF-α thereby improved quality of life in healthy volunteers. 144 Iauril soft gels containing curcumin, quercetin, hyaluronic acid and chondroitin sulfate reduced dysmenorrhea, chronic pelvic pain, and dysuria in patients with endometriosis. 145 Killox, another curcumin formulation, (190 mg curcuminoids, 20 mg resveratrol, 100 mg NAC, 6 mg zinc with the formulation of enterosoma technology) reduced postoperative irritation duration and complications in patients who underwent transurethral resection of prostate, transurethral resection of bladder and with benign prostate hyperplasia (BPH). 146 The formulation did not induce any side effects and it was also found to be safe and well-tolerated in these patients. 146 In addition, LCD capsules (soft gel capsules containing lutein 20 mg, curcumin 200 mg, zeaxanthin 4 mg from marigold flower extract, algal source vitamin D3 600 IU, medium chain TG oil, linseed oil, olive oil, sunflower lecithin, tocopherol and thyme oil) improved Schirmer’s strip wetness length, tear volume, TBUT score, SPEED score, OSDI score, corneal and conjunctival staining score, tear osmolarity, and MMP-9 positive score with comparative safety and no adverse side effects in patients with dry eye syndrome in contrast to soyabean oil as placebo. 147 Moreover, natural product capsules manufactured by Vitacost consisting of 150 mg curcumin, 75 mg resveratrol, and 150 mg epigallocatechin-3-gallate for each 500 mg tablet was shown to reduce TNF-α induced NF-κB activation in healthy volunteers. 148 In another study administration of nutraceuticals with anti-inflammatory, oxidative, and nitrosative stress (NAIOS) containing l -carnitine, coenzyme Q10, curcumin, lipoic acid, quercetin or NAC, glutamine, taurine, and zinc reduced IgM mediated autoimmune responses, fibromyalgia, and fatigue rating and severity of diseases in patients suffering from myalgic encephalomyelitis/chronic fatigue syndrome. 149 Further, PureVida (460 mg of fish oil, 125 mg of Hytolive powder containing 12.5 mg of hydroxytyrosol, 50 mg of curcumin extract) formulation relieved pain and reduced CRP in breast cancer patients with no serious adverse side effects. 150 Another study showed that Reglicem formulation (chromium picolinate 100 μcg Cr, 200 mg curcumin dry extract, 200 mg berberine dry extract, 300 mg inositol, 40 mg banaba dry extract with 1% corosolic acid, silicon dioxide, magnesium stearate, dicalcium phosphate, microcrystalline cellulose) reduced FBS, postprandial blood sugar (PPBS), HbA1c, insulin, homeostatic model assessment (HOMA)-index, TG, TC, and CRP levels in fasting dysglycemia patients. 151 In another clinical trial, hot water extract of curcumin with or without pure curcumin powder for 8 weeks improved the water content of the skin and suppressed trans-epidermal water loss in healthy subjects. 152 Furthermore, Nutrafol women’s capsule formulation (a proprietary blend of clinically tested and bio-optimized phytoactive extracts, vitamins, minerals, and botanicals including standardized extracts of ashwagandha, curcumin, piperine, capsaicin, hydrolyzed marine collagen, hyaluronic acid, organic kelp) augmented hair growth, quality, volume and thickness without any side effects in women with self-perceived hair thinning. 153

Taken together, these results indicated that the first-generation curcumin formulations enhanced the absorption and bioavailability of pure curcumin and were effective against various ailments including autoimmune diseases, cancer, diabetes, hemoglobinopathies, oral diseases, and PMS.

Second-Generation Curcumin Formulation

Curcumin is readily soluble in fat. Hence, newer formulations have been developed to enhance the solubility of curcumin to enhance its absorption and bioavailability. 18 , 48 Over the years, various technologies have been utilized to enhance its solubility including the usage of polysorbates, phospholipid complexes, liquid droplet nanomicelle, and spray drying. 44 The novel curcumin second and third-generation formulations and their antichronic disease effects have been highlighted in Figure 2 .

These second-generation formulations have shown excellent bioavailability and antiarthritic, anticancer, antidiabetic, and antiviral activities in numerous clinical trials ( Table 2 ). For example, oral intake of 500 mg/day novel Actbiome formulation, (curcumin and asafetida complex was incorporated into turmeric fiber) for 8 weeks showed a reduction in IL-10 and gastrointestinal symptom rating scale (GSRS) score and increased fecal bifidobacteria, fecal lactobacilli, and ideal stool form and frequency without any side effects in healthy subjects. 154 Another study showed that a polysorbate formulation of curcumin named BioCurc/CLDM (85% curcumin, 13% desmethoxycurcumin, 2% bisdemethoxycurcumin, lauryl macrogol-32 glycerides, polysorbate-20, dl -alpha-tocopherol, hydroxy prolyl cellulose) (6 tablets, cross-over study) possess excellent absorption and bioavailability and safety in healthy individuals. 155 In addition, cyclodextrin formulation of curcumin known as Cavacurcumin along with omega-3 fatty acids (ω-3 FA), astaxanthin, gamma linoleic GLA, tocotrienols, hydroxy tyrosol, and vitamin D3 resulted in substantial reduction of hs-CRP, and SBP in healthy volunteers. This regimen was also well-tolerated without any adverse side effects. 156 Additionally, curcumin has also been formulated with hydrophilic carriers (CHC) to suppress its hydrophobicity and to enhance its solubility. The CHC formulation has been shown to increase curcumin bioavailability compared to standardized curcumin mixture, phytosomal curcumin formulation, and curcumin-turmeric volatile oil formulation in healthy volunteers. 157 This formulation has also been reported to be safe and did not cause any side effects in both healthy subjects and diabetic patients. 157 , 158 Besides, curcumin phosphatidylcholine along with irinotecan treatment has been shown to delay the disease progression without serious toxicity in patients with solid tumors. 41 Another phytosomal curcumin formulation, Curserin (200 mg curcumin, 480 mg phosphatidylcholine, 120 mg phosphatidylserine, and 8 mg piperine) increased HDL-C and decreased FPG, fasting plasma insulin (FPI), GGT, HOMA for insulin resistance (HOMA-IR), glutamate oxaloacetate transaminase (GOT), glutamate pyruvate transaminase (GPT), lipid accumulation product (LAP), fatty liver index (FLI), TG, non-LDL-C, and hepatic steatosis index (HSI) in obese patients without adverse side effects. 159 In another study, oral intake of curcuminoid micelles capsules containing 20.1 mg curcumin, 3.9 mg demethoxycurcumin, and 0.5 mg bisdemethoxycurcumin was shown to be safe, well-tolerated, and enhanced the bioavailability of curcumin in healthy subjects. 160 , 161 Also, micellar curcumin formulation increased intratumor pH and inorganic phosphate levels in glioblastoma patients with minor side effects. 162 In another study, this formulation was shown to reduce creatinine kinase MB (CK-MB) in myocardial infarction patients. 163

Another phospholipidic formulation FLAVOMEGA containing acetylcarnitine, acesulfame potassium, antiagglomerant, ascorbic acid, baicalin, coenzyme Q10, fructose, green tea catechins, phospholipidic curcumin, skullcap, and sucralose improved muscle strength, performance, and isokinetic knee extension and suppressed CK, reactive oxygen species, valine and free fatty acids in patients with Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and limb-girdle muscular dystrophy (LGMD). 164 This formulation was also found to be safe, and well-tolerated without causing side effects. 164 Moreover, curcumin polysorbate formulation Flexofytol remarkably reduced Coll2-1, CRP, and global disease assessment activity in osteoarthritis patients in 3 months. 165 In another study, Flexofytol along with Boswellia extract pine bark extract, and methylsulfonyl methane for 12 weeks reduced activity impairment and FIHOA score without any significant adverse effects in osteoarthritis patients. 166 Another formulation HydroCurc consists of 80% curcumin, 17% demethoxycurcumin, and 3% bisdemethoxycurcumin entrapped in a LipiSperse delivery system, was demonstrated to inhibit the formation of thiobarbituric acid reactive substances (TBARS), TNF-α, IL-6, and relieved fatigue. 167 The formulation itself did not cause any side effects and further reduced the iron-induced gastrointestinal (GI) side effects. 167 Also, a single dose of HydroCurc along with maltodextrin enhanced IL-6, and IL-10, and reduced TC, pain, and capillary lactate dehydrogenase during the postexercise period in healthy young men. 168 In another study, Lipocurc formulation was shown to reduce PSA, CEA, and CA 19-9 in patients with advanced metastatic tumors without any side effects. 169 Although, lecithinized curcumin did not affect vitamin E in metabolic syndrome patients, reduced ratio of vitamin E/LDL, vitamin E/TC, and vitamin E/TG were noticed. 170

As mentioned curcumin is least soluble in water with an estimated solubility of 11 ng/mL in alkaline conditions while it is readily soluble in lipids or fats. 43 , 171 , 172 Hence, efforts have been made to develop various lipid or phospholipid curcumin formulations and several of these formulations have shown tremendous potential as therapeutic agents. 173 For example, Meriva, a lecithin delivery method for curcumin, has better tissue dispersion and bioavailability than the unformulated natural substance. 64 , 173 This novel second-generation formulation has been shown to be safe and well-tolerated at a dose of 250 mg/day to 4 g/day for a period of 7 days to 8 months and did not cause any side effects both in healthy subjects and patients. 173 − 192 Moreover, this formation has been shown to ameliorate metabolic disorders including diabetes-associated edema and microangiopathy, hypercholesterolemia, metabolic syndrome, and NAFLD. 176 , 177 , 179 − 184 , 193 − 195 In various clinical trials, this formulation reduced skin flux, peripheral edema, retinal edema, LDL-C, TC, TG, LDL-C, non-HDL-C, uric acid, BMI, waist circumference, hip circumference, AST, ALT, portal vein diameter, liver size, 3-methyl-2-oxovaleric acid, 3-citrate, hippurate, hydroxyisobutyrate, indoxyl sulfate, α-ketoglutarate, kynurenine, methylamine, succinate, trimethylamine, chenodeoxy cholic acid, lithocholic acid, taurocholic acid, leptin, MutL homologue 1 (MLH1), and MutS homologue 2 (MSH2), and increased adiponectin levels, zinc levels, Zinc to copper ratio, PO 2 , visual acuity, microcirculation score, in patients. 176 , 177 , 179 − 184 , 193 , 194 In another study, administration of Meriva (1 g/day) for 3 or 6 months caused a substantial reduction in MCP-1, IL-4, IFNγ, TBARS, p -cresyl sulfate, carbohydrate intake, protein intake, total fiber intake, phosphorus and potassium intake, and gut microbes such as Escherichia - Shigella , Enterobacter verrucomicrobia , Firmicutes, and improved other species of microbes including Lactobacillaceae spp., Lachnoclostridium spp., Lachnospiraceae family, and Prevotellaceae without side effects in patients suffering from chronic kidney diseases. 175 In addition, this formulation showed potential anticancer activities against solid tumors with enhanced safety, tolerability, and minimal adverse side effects. 187 − 189 , 191 , 192 It also improved response rate, stable disease period, inflammation, quality of life, and survival rate, and reduced the burden of chemotherapeutic side effects among these patients. 187 − 189 , 191 , 192 In addition, Meriva mitigated inflammatory markers such as CRP, IL-1β, IL-6, ESR, sCD40L, and sVCAM-1, WOMAC score, Karnofsky scale score, stiffness, negative effects on social function, and boosted physical performance capacity in osteoarthritis with excellent safety and tolerability ( Figure 2 ). 185 , 186 It also reduced the risk of development of T2D and Alzheimer’s disease in adults of age between 30 and 70 years. 190 Another study showed that this formulation (1 g or 4g/day) reduced the severity of gulf war illness disease without any serious side effects. 178 Moreover, Meriva along with fish oil reduced postprandial insulin levels in healthy subjects whereas Meriva with phytosterol reduced cardiovascular disease (CVD) risk in hypercholesterolemia patients. 179 , 196 , 197

In another study, Meriva with anthocyanin has shown improvement in colorectal adenomatous polypos symptoms and it reduced NF-κB and Ki67 levels. 198 Further, another Meriva formulation called Algocur (each tablet contains 1g of Meriva) improved physical performance and reduced pain in men rugby players with osteo-muscular pain. 199 This formulation also showed to be safe and well-tolerated among these men. 199 Wolf and colleagues developed three different lipidated curcumin—NE65, NLC65, and NLC80—formulations reduced trans-epidermal water loss and modulated skin barrier functions in healthy subjects. 200 Another study showed that supplementation of Valdone curcumin soft gel (utilized self-emulsifying drug delivery system) improved clinical response and remission rates in ulcerative colitis patients. 201 Furthermore, topical application of curcuminoid-phosphatidyl choline formulated cream enhanced repigmentation in vitiligo patients. 202 However, another phytosomal curcumin formulation was shown to possess no considerable effect on aryl esterase activities in MetS patients. 203 Also, several studies have also revealed that phospholipidated formulations of both curcumin and curcuminoids were not considerably effective in treating patients with MetS. 204 − 208

Nanoencapsulation or nanoformulation of curcumin is another promising strategy both to increase bioavailability and to decrease curcumin degradation rate in vivo. 23 , 43 Several synthetic and natural polymers, such as chitosan, N -isopropylacrylamide (NIPAAM), N -vinyl-2- polyethylene glycol monoacrylate (NIPAAM [VP/PEG A]), poly(lactic- co -glycolic acid), pyrrolidone, poly(vinyl alcohol) (PVA), and silk fibroin have been developed for curcumin nanoencapsulation. 43 , 209 − 212 Over the years, nanotechnology-based therapeutic delivery methods, including nanoparticles, liposomes, and nanoemulsions, have been developed. 213 , 214 The use of biochemical changes at the tissue microenvironment level in diseased states to initiate and activate drug release has replaced more traditional drug release mechanisms with the controlled-release mechanisms by novel engineered nanoparticle drug delivery systems. 214 , 215 Data indicated that these formulations increased treatment effectiveness while concurrently decreasing harmful side effects. 211 , 212 , 216 , 217 The novel nanocurcumin formulation developed by Exir Nano Sina (Iran) has shown excellent therapeutic efficacy in various diseases such as amyotrophic lateral sclerosis (ALS), ankylosing spondylitis (AS), arthritis, cancer, COVID-19, CVDs, diabetes, infertility, MetS, NAFLD, neurological and psychological disorders without side effects ( Figure 3 ). 195 , 218 − 235 Administration of this formulation for 12 months increased the survival rate in ALS patients. 218 It also reduced RORγ t, IL-17, IL-23, miR-141, miR-155, miR-200, and symptoms in AS patients. 219 The antiarthritic potential of this formulation has been evidenced by its capacity in suppressing CRP, CD4 + and CD8 T + cells, Th 17 cells, B cells, miRNA-155, miRNA-138, miRNA-16 and VAS score, and augmenting Treg cells without any adverse events in the clinical trials involving osteoarthritis and RA patients. 225 , 226 , 236 It was also shown to be effective in treating Behcet’s disease where it improved Treg cells, FOXP3, TGF-β, IL-10, miRNA-25, and miRNA-106b. 237

Multiple clinical trials have shown its potential in treating COVID-19 disease with admirable safety and tolerability. Nanocurcumin formulation in COVID-19 patients led to reduced levels of GM-CSF, IFNγ, IL-1β, IL-6, IL-17, IL-18, IL-21, IL-23, RORγ t, T-box transcription factor 21 (TBX21), and TNF-α, and induced FOXP3, IL-4, IL-10, IL-35, and TGF-β levels. 238 − 242 It also improved lymphocyte count, oxygen saturation levels, symptoms, and Treg cell frequency and reduced symptom resolution time, hospitalized duration, and mortality rate in COVID-19 patients. 221 , 222 , 238 − 243 Several studies have also revealed the beneficial effects of nanocurcumin formulation in treating critically ill patients with sepsis. Nanocurcumin from Exir-Nano-Sina (Iran) suppressed Bcl-2, inflammatory molecules such as ICAM-1, IL-1β, IL-6, IL-18, TLR-4, TNF-α, and VCAM-1, creatinine, lipid profile, liver enzymes and reduced mechanical ventilation period in these patients. 227 , 244 , 245 In addition, nanocurcumin treatment enhanced clinical response rate and ameliorated radiation-induced dermatitis in various cancers including bladder, head and neck, and prostate cancers. 224 , 246 , 247 It also reduced DNA damage and micronuclei formation in lymphocytes of thyroid cancer patients. 228 Moreover, the antidiabetic properties of nanocurcumin were attributed their capacity in reducing FBG, glycated Hb, insulin, hs-CRP, TC, TAC, TN, LDL-C, VLDL-C, TC/HDL-C, MDA, and augmented insulin sensitivity, TAC, peroxisome proliferator-activated receptor gamma (PPARγ), LDLR, and GSH levels in T2D patients. 248 − 251 It also suppressed neuropathy, depression, and anxiety in T2D-associated peripheral neuropathy patients. 251 , 252 Nanocurcumin supplementation for 10 weeks improved sperm count, sperm motility, and testosterone levels in patients with infertility complaints. 229 This study also showed that nanocurcumin increased testosterone levels and reduced follicular stimulating hormone (FSH), luteinizing hormone (LH), and prolactin levels, although not statistically significant. 229 This formulation has also been shown to decrease TG, HOMA-β, and MDA, and upregulate adiponectin levels and TAC in MetS patients. 230 , 253 Further, treatment with this formulation remarkably reduced the degree of fatty liver, liver enzymes, lipid profile, and inflammatory mediators in patients with NAFLD. 254 This formulation was also effective in treating neurological disorders such as migraine, multiple sclerosis, and Parkinson’s disease and was able to improve disease severity, symptoms, and deregulated miRNAs with no or mild GI side effects. 231 , 232 , 255 − 260 It also reduced pain, severity, lesion area, and burning sensation in patients with various oral diseases including gingivitis, mucositis, and OLP. 247 , 261 − 264 In another study, this formulation enhanced the responsive rate while reducing the positive and negative PANSS subscale score in schizophrenia patients. 233 Further, nanocurcumin formulation from Theravalues Corp., Japan was demonstrated to downregulate IL-6, hs-CRP, MDA, and upregulate IL-10, brain-derived neurotrophic factor (BDNF), and TAC in MetS patients. 265 Furthermore, several other nanocurcumin formulations have also been developed by various laboratories and these formulations have shown tremendous potential in helping healthy subjects and treating various chronic diseases such as arthritis, cancer, NAFLD, neurological disorders, oral diseases, and skin diseases. 266 − 279 Thus, nanocurcumin formulation with enhanced bioavailability and safety has been promising in treating several human diseases.

A distinctive example of a submicron crystal dispersion of curcumin known as Theracurmin was reported to have 27-fold higher bioavailability in comparison with pure curcumin. 49 Increasing lines of evidence also suggested its enhanced bioavailability with acceptable safety and mild side effects in healthy subjects and cancer patients ( Figure 2 ). 116 , 280 − 286 It has also been shown to reduce exercise-induced muscle soreness and increased the range of motion. 287 , 288 In postmenopausal women, it reduced brachial SBP. 289 This formulation also improved clinical response rate and lesion healing and reduced endoscopic disease severity in Crohn’s disease patients. 290 In another study, Theracurmin significantly reduced mRNA expression of IL-6 in PBMCs and serum levels of IL-6 in hemodialysis patients. 291 Another salient example of clinical benefits of Theracurmin comes from the trial on osteochondral diseases in which it reduced roughness in the femur bone and stiffness in the knee joint. 292 It also inhibited the raise in oxidized LDL in both COPD and T2D patients. 293 , 294

Collectively, these studies suggest that second-generation formulations of curcumin improved the bioavailability of curcumin and their significance drives the ancillary goal to develop them as therapeutic drugs.

Third-Generation Curcumin Formulation

An expansive frontier in nutraceuticals is unfolding third-generation curcumin formulation via increasing the bioavailability of “free” curcuminoids without using synthetic polysorbates and/or emulsifiers. 44 , 295 These formulations are well established to have superior absorption, BBB-permeability, cellular uptake, and better tissue distribution. 295 , 296 Based on the published literature, these formulations have greater than 100-fold higher bioavailability compared to pure curcumin. 47 Besides, these formulations are devoid of adulterants and contaminants, making them safer and nongenotoxic and nonhepatotoxic for long-time clinical use. 44 Indeed, third-generation formulations have been developed recently and these formulations include curcumin galactomannan formulation or CurQfen (noncovalent complex between curcumin and fenugreek galactomannans), curcuRouge (Starch and curcumin formulation), Curcuwin Ultra (cellulosic derivatives and curcumin formulation), and Longvida (soy lecithin and curcumin formulation) ( Figure 2 ). 47 , 295 , 297 CurQfen was shown to be safe and well-tolerated and had no adverse side effects have been reported in clinical trials. 44 , 298 − 301 This formulation also improved α- and β-waves of EEG, memory improvement, and reduced choice-based-visual reaction time in healthy subjects. 302 It also improved walking performance, VAS score, and WOMAC score, and inhibited the rise in hs-CRP, IL-1β, and IL-6 levels in osteoarthritis patients. 298 , 301 In addition, its antiobesity and anti-CVD properties were attributed to its increased levels of HDL and reduced levels of homocysteine within 12 weeks of treatment. 300 Besides, to a certain extent, this formulation relieved occupational stress as evidenced by improvement in QoL, SOD, GPx, GSH, and fatigue. 299 In another study, curcuRouge was demonstrated to reduce the neutrophil to lymphocyte ratio without any safety issues in healthy subjects. 303 Another formulation Curcuwin Ultra+ showed enhanced bioavailability and was found to be safe in healthy subjects. 304 Another next-generation formulation with superior bioavailability, Longvida was also elucidated to reduce fatigue, and oxidative stress, tension, and anxiety, and improved mood-related issues, and cognitive functions in healthy individuals with excellent safety and no side effects. 305 − 308 Moreover, clinical trials on obese patients have revealed that Longvida intake improved cerebral artery stiffness, cerebrovascular responsiveness, and lipid profile without side effects. 309 − 311 It has also been shown to be beneficial in treating both OSF and osteoarthritis. 312 , 313 Another illuminating clinical trial evidenced the use of Longvida in detecting amyloid spots in the retina of Alzheimer’s patients and reported that this formulation exhibits a greater capacity to identify these spots in positron emission tomography (PET) scanning compared to conventional amyloid PET in longitudinal evaluation of amyloid risk and neurodegeneration (LEARN) study. 314

Certainly, these clues warrant further investigations on third-generation curcumin formulations as a novel nutraceutical formulation in diagnosing and treating various ailments.

Conclusion

Advances in chemistry and technologies have provided the versatility and tools to develop a range of innovative curcumin formulations with considerable improvement in oral bioavailability and safety. Decades of research on curcumin and its formulations resulted in the increased oral bioavailability of curcumin from 11 ng/mL to 626.98 μg/mL. These curcumin formulations were found to be safe and well-tolerated even at higher doses ranging from 2 g/day to 12 g/day and for a prolonged duration of 6 months to an year. The simplest first-generation formulation with adjuvants to second-generation with polysorbates to third-generation with only natural material have shown tremendous absorption capacity, cellular uptake, and safety not only in diseased but also in healthy subjects providing the evidence of disease prevention and treatment capability of these formulations. As we noted at this time, few of these regimens including curcumin plus piperine combination, BCM-95, nanocurcumin, Meriva, and Theracurmin have been tested clinically and are effective against chronic diseases such as arthritis, autoimmune diseases, cancer, diabetes, endometriosis, hemoglobinopathies, metabolic syndrome, neurological disorders, obesity, oral diseases, psychological disorders, and skin diseases. All the formulations have been shown beneficial effects compared to either placebo such as calcium phosphate, lactose, rice flour, and starch, or the standard care treatment. Major grade 3 side effects, GI intolerability, and hepatotoxicity were reported when curcumin was administered intravenously earlier. Nevertheless, the minor side effects in most of these trials with oral intake of curcumin formulations include cold, irritation, indigestibility, and nausea which in few cases might be attributed to adjuvants and emulsifiers. However, clinical studies are scarce at this time on upcoming and more promising third-generation formulations. Notably, it is advisable to opt for highly bioavailable curcumin formulations that have demonstrated their therapeutic efficacy at a relatively low dosage of 80–500 mg/day. Further, most of the clinical trials conducted were restricted to a small number of patient groups. However, more research is needed to examine the safety and effectiveness of curcumin formulations in both large and diverse patient populations with different phases of the disease. As such, all these formulations cannot be inherently compared due to dissimilarities in the dose, duration of treatment, clinical study design, formulation type, the method used for analysis, and population disparity. Recently, as detailed earlier, curcumin formulation was also used to diagnose the amyloid spots clinically. Therefore, curcumin formulations have significant potential to serve as preventive, diagnostic, and therapeutic entities.

Author Contributions

M.H. contributed to the initial drafting of the manuscript, review of literature, table preparation, visualization, and overall editing; S.G. contributed to the initial drafting of the manuscript and overall editing; B.B. and R.V. provided critical overall manuscript editing and revision; A.B.K. contributed to conceptualization, funding, overall supervision, and supported review development and overall editing.

This project was supported by BT/556/NE/U-Excel/2016 grant awarded to A.B.K. by Department of Biotechnology (DBT), Government of India.

The authors declare no competing financial interest.

Acknowledgments

Mangala Hegde acknowledges Science and Engineering Research Board (SERB)-National Post-Doctoral Fellowship (NPDF) (PDF/2021/004053). All the figures were created using BioRender.com .

References

Tabas I. ; Glass C. K. Anti-inflammatory therapy in chronic disease: challenges and opportunities . Science 2013 , 339 ( 6116 ), 166 – 172 . 10.1126/science.1230720 . 23307734 PMC3608517

Cote B. ; Elbarbry F. ; Bui F. ; Su J. W. ; Seo K. ; Nguyen A. ; Lee M. ; Rao D. A. Mechanistic Basis for the Role of Phytochemicals in Inflammation-Associated Chronic Diseases . Molecules 2022 , 27 ( 3 ), 781 10.3390/molecules27030781 . 35164043 PMC8838908

Kunnumakkara A. B. ; Sung B. ; Ravindran J. ; Diagaradjane P. ; Deorukhkar A. ; Dey S. ; Koca C. ; Tong Z. ; Gelovani J. G. ; Guha S. ; et al. Zyflamend suppresses growth and sensitizes human pancreatic tumors to gemcitabine in an orthotopic mouse model through modulation of multiple targets . Int. J. Cancer 2012 , 131 ( 3 ), E292 – 303 . 10.1002/ijc.26442 . 21935918 PMC3288649

Kunnumakkara A. B. ; Nair A. S. ; Ahn K. S. ; Pandey M. K. ; Yi Z. ; Liu M. ; Aggarwal B. B. Gossypin, a pentahydroxy glucosyl flavone, inhibits the transforming growth factor beta-activated kinase-1-mediated NF-kappaB activation pathway, leading to potentiation of apoptosis, suppression of invasion, and abrogation of osteoclastogenesis . Blood 2007 , 109 ( 12 ), 5112 – 5121 . 10.1182/blood-2007-01-067256 . 17332240 PMC1890830

Quinn B. J. ; Dallos M. ; Kitagawa H. ; Kunnumakkara A. B. ; Memmott R. M. ; Hollander M. C. ; Gills J. J. ; Dennis P. A. Inhibition of lung tumorigenesis by metformin is associated with decreased plasma IGF-I and diminished receptor tyrosine kinase signaling . Cancer Prev Res. (Phila) 2013 , 6 ( 8 ), 801 – 810 . 10.1158/1940-6207.CAPR-13-0058-T . 23771523 PMC3740378

Brockmueller A. ; Mueller A. L. ; Kunnumakkara A. B. ; Aggarwal B. B. ; Shakibaei M. Multifunctionality of Calebin A in inflammation, chronic diseases and cancer . Front Oncol 2022 , 12 , 962066 10.3389/fonc.2022.962066 . 36185259 PMC9523377

Hegde M. ; Girisa S. ; Naliyadhara N. ; Kumar A. ; Alqahtani M. S. ; Abbas M. ; Mohan C. D. ; Warrier S. ; Hui K. M. ; Rangappa K. S. ; et al. Natural compounds targeting nuclear receptors for effective cancer therapy . Cancer Metastasis Rev. 2022 , 10.1007/s10555-022-10068-w . 36482154

Bordoloi D. ; Banik K. ; Padmavathi G. ; Vikkurthi R. ; Harsha C. ; Roy N. K. ; Singh A. K. ; Monisha J. ; Wang H. ; Kumar A. P. TIPE2 Induced the Proliferation, Survival, and Migration of Lung Cancer Cells Through Modulation of Akt/mTOR/NF-kappaB Signaling Cascade . Biomolecules 2019 , 9 ( 12 ), 836 10.3390/biom9120836 . 31817720 PMC6995575

Zhao H. ; Wu L. ; Yan G. ; Chen Y. ; Zhou M. ; Wu Y. ; Li Y. Inflammation and tumor progression: signaling pathways and targeted intervention . Signal Transduct Target Ther 2021 , 6 ( 1 ), 263 10.1038/s41392-021-00658-5 . 34248142 PMC8273155

Tewari D. ; Patni P. ; Bishayee A. ; Sah A. N. ; Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy . Semin Cancer Biol. 2022 , 80 , 1 – 17 . 10.1016/j.semcancer.2019.12.008 . 31866476

Zhong Z. ; Vong C. T. ; Chen F. ; Tan H. ; Zhang C. ; Wang N. ; Cui L. ; Wang Y. ; Feng Y. Immunomodulatory potential of natural products from herbal medicines as immune checkpoints inhibitors: Helping to fight against cancer via multiple targets . Med. Res. Rev. 2022 , 42 ( 3 ), 1246 – 1279 . 10.1002/med.21876 . 35028953 PMC9306614

Singla R. K. ; De R. ; Efferth T. ; Mezzetti B. ; Sahab Uddin M. ; Sanusi ; Ntie-Kang F. ; Wang D. ; Schultz F. ; Kharat K. R. ; et al. The International Natural Product Sciences Taskforce (INPST) and the power of Twitter networking exemplified through #INPST hashtag analysis . Phytomedicine 2023 , 108 , 154520 10.1016/j.phymed.2022.154520 . 36334386

Pratheeshkumar P. ; Sreekala C. ; Zhang Z. ; Budhraja A. ; Ding S. ; Son Y. O. ; Wang X. ; Hitron A. ; Hyun-Jung K. ; Wang L. ; et al. Cancer prevention with promising natural products: mechanisms of action and molecular targets . Anticancer Agents Med. Chem. 2012 , 12 ( 10 ), 1159 – 1184 . 10.2174/187152012803833035 . 22583402 PMC4983770

Cavalcanti R. ; Koshima C. ; Forster-Carneiro T. ; Gomes M. ; Rostagno M. ; Prado J. ; Meireles M. Uses and applications of extracts from natural sources . Natural Product Extraction ; Royal Society of Chemistry , 2022 ; pp 1 – 65 ; DOI: 10.1039/9781839165894-00001 .

Aggarwal B. B. ; Kunnumakkara A. B. Molecular Targets and Therapeutic Uses of Spices: Modern Uses for Ancient Medicine ; World Scientific , 2009 .

Gupta S. C. ; Sung B. ; Kim J. H. ; Prasad S. ; Li S. ; Aggarwal B. B. Multitargeting by turmeric, the golden spice: From kitchen to clinic . Mol. Nutr Food Res. 2013 , 57 ( 9 ), 1510 – 1528 . 10.1002/mnfr.201100741 . 22887802

Liu Z. ; Smart J. D. ; Pannala A. S. Recent developments in formulation design for improving oral bioavailability of curcumin: a review . Journal of drug delivery science and technology 2020 , 60 , 102082 10.1016/j.jddst.2020.102082 .

Anand P. ; Kunnumakkara A. B. ; Newman R. A. ; Aggarwal B. B. Bioavailability of curcumin: problems and promises . Mol. Pharmaceutics 2007 , 4 ( 6 ), 807 – 818 . 10.1021/mp700113r . 17999464

Araiza-Calahorra A. ; Akhtar M. ; Sarkar A. Recent advances in emulsion-based delivery approaches for curcumin: From encapsulation to bioaccessibility . Trends in Food Science & Technology 2018 , 71 , 155 – 169 . 10.1016/j.tifs.2017.11.009 .

Esatbeyoglu T. ; Huebbe P. ; Ernst I. M. ; Chin D. ; Wagner A. E. ; Rimbach G. Curcumin--from molecule to biological function . Angew. Chem., Int. Ed. Engl. 2012 , 51 ( 22 ), 5308 – 5332 . 10.1002/anie.201107724 . 22566109

Zielinska A. ; Alves H. ; Marques V. ; Durazzo A. ; Lucarini M. ; Alves T. F. ; Morsink M. ; Willemen N. ; Eder P. ; Chaud M. V. Properties, Extraction Methods, and Delivery Systems for Curcumin as a Natural Source of Beneficial Health Effects . Medicina (Kaunas) 2020 , 56 ( 7 ), 336 10.3390/medicina56070336 . 32635279 PMC7404808

Yallapu M. M. ; Nagesh P. K. ; Jaggi M. ; Chauhan S. C. Therapeutic Applications of Curcumin Nanoformulations . AAPS J. 2015 , 17 ( 6 ), 1341 – 1356 . 10.1208/s12248-015-9811-z . 26335307 PMC4627456

Yallapu M. M. ; Jaggi M. ; Chauhan S. C. Curcumin nanoformulations: a future nanomedicine for cancer . Drug Discov Today 2012 , 17 ( 1–2 ), 71 – 80 . 10.1016/j.drudis.2011.09.009 . 21959306 PMC3259195

Gupta S. C. ; Patchva S. ; Aggarwal B. B. Therapeutic roles of curcumin: lessons learned from clinical trials . AAPS J. 2013 , 15 ( 1 ), 195 – 218 . 10.1208/s12248-012-9432-8 . 23143785 PMC3535097

Amalraj A. ; Sukumaran N. P. ; Kunnumakkara A. B. ; Gopi S. The Chemistry and Biological Activities of Curcuminoids: Impacts on Neurological Disorders . Curcumin for Neurological and Psychiatric Disorders ; Elsevier , 2019 ; pp 105 – 127 .

Kunnumakkara A. B. ; Bordoloi D. ; Padmavathi G. ; Monisha J. ; Roy N. K. ; Prasad S. ; Aggarwal B. B. Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases . Br. J. Pharmacol. 2017 , 174 ( 11 ), 1325 – 1348 . 10.1111/bph.13621 . 27638428 PMC5429333

Girisa S. ; Kumar A. ; Rana V. ; Parama D. ; Daimary U. D. ; Warnakulasuriya S. ; Kumar A. P. ; Kunnumakkara A. B. From Simple Mouth Cavities to Complex Oral Mucosal Disorders-Curcuminoids as a Promising Therapeutic Approach . ACS Pharmacol Transl Sci. 2021 , 4 ( 2 ), 647 – 665 . 10.1021/acsptsci.1c00017 . 33860191 PMC8033761

Kumar A. ; Harsha C. ; Parama D. ; Girisa S. ; Daimary U. D. ; Mao X. ; Kunnumakkara A. B. Current clinical developments in curcumin-based therapeutics for cancer and chronic diseases . Phytother Res. 2021 , 35 ( 12 ), 6768 – 6801 . 10.1002/ptr.7264 . 34498308

Shabnam B. ; Harsha C. ; Thakur K. K. ; Khatoon E. ; Kunnumakkara A. B. Curcumin: a potential molecule for the prevention and treatment of inflammatory diseases . In The Chemistry and Bioactive Components of Turmeric ; Royal Society of Chemistry , 2020 ; pp 150 – 171 .

Jacob J. ; Amalraj A. ; Raj K. K. J. ; Divya C. ; Kunnumakkara A. B. ; Gopi S. A novel bioavailable hydrogenated curcuminoids formulation (CuroWhite) improves symptoms and diagnostic indicators in rheumatoid arthritis patients - A randomized, double blind and placebo controlled study . J. Tradit Complement Med. 2019 , 9 ( 4 ), 346 – 352 . 10.1016/j.jtcme.2018.06.001 . 31453131 PMC6702143

Kiso Y. ; Suzuki Y. ; Watanabe N. ; Oshima Y. ; Hikino H. Antihepatotoxic principles of Curcuma longa rhizomes . Planta Med. 1983 , 49 ( 3 ), 185 – 187 . 10.1055/s-2007-969845 . 6657788

Venkatesan N. Curcumin attenuation of acute adriamycin myocardial toxicity in rats . Br. J. Pharmacol. 1998 , 124 ( 3 ), 425 – 427 . 10.1038/sj.bjp.0701877 . 9647462 PMC1565424

Venkatesan N. ; Punithavathi D. ; Arumugam V. Curcumin prevents adriamycin nephrotoxicity in rats . Br. J. Pharmacol. 2000 , 129 ( 2 ), 231 – 234 . 10.1038/sj.bjp.0703067 . 10694226 PMC1571849

Srinivasan M. Effect of curcumin on blood sugar as seen in a diabetic subject . Indian J. Med. Sci. 1972 , 26 ( 4 ), 269 – 270 . 4637293

Arun N. ; Nalini N. Efficacy of turmeric on blood sugar and polyol pathway in diabetic albino rats . Plant Foods Hum Nutr 2002 , 57 ( 1 ), 41 – 52 . 10.1023/A:1013106527829 . 11855620

Kunnumakkara A. B. ; Bordoloi D. ; Harsha C. ; Banik K. ; Gupta S. C. ; Aggarwal B. B. Curcumin mediates anticancer effects by modulating multiple cell signaling pathways . Clin Sci. (Lond) 2017 , 131 ( 15 ), 1781 – 1799 . 10.1042/CS20160935 . 28679846

Bordoloi D. ; Kunnumakkara A. B. The potential of curcumin: a multitargeting agent in cancer cell chemosensitization . In Role of nutraceuticals in cancer chemosensitization ; Elsevier , 2018 ; pp 31 – 60 .

Kocaadam B. ; Sanlier N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health . Crit Rev. Food Sci. Nutr 2017 , 57 ( 13 ), 2889 – 2895 . 10.1080/10408398.2015.1077195 . 26528921

Yeung A. W. K. ; Horbanczuk M. ; Tzvetkov N. T. ; Mocan A. ; Carradori S. ; Maggi F. ; Marchewka J. ; Sut S. ; Dall’Acqua S. ; Gan R. Y. ; et al. Curcumin: Total-Scale Analysis of the Scientific Literature . Molecules 2019 , 24 ( 7 ), 1393 10.3390/molecules24071393 . 30970601 PMC6480685

Klickovic U. ; Doberer D. ; Gouya G. ; Aschauer S. ; Weisshaar S. ; Storka A. ; Bilban M. ; Wolzt M. Human pharmacokinetics of high dose oral curcumin and its effect on heme oxygenase-1 expression in healthy male subjects . Biomed Res. Int. 2014 , 2014 , 458592 10.1155/2014/458592 . 24592391 PMC3925623

Gbolahan O. B. ; O’Neil B. H. ; McRee A. J. ; Sanoff H. K. ; Fallon J. K. ; Smith P. C. ; Ivanova A. ; Moore D. T. ; Dumond J. ; Asher G. N. A phase I evaluation of the effect of curcumin on dose-limiting toxicity and pharmacokinetics of irinotecan in participants with solid tumors . Clin Transl Sci. 2022 , 15 ( 5 ), 1304 – 1315 . 10.1111/cts.13250 . 35157783 PMC9099132

Stohs S. J. ; Chen O. ; Ray S. D. ; Ji J. ; Bucci L. R. ; Preuss H. G. Highly Bioavailable Forms of Curcumin and Promising Avenues for Curcumin-Based Research and Application: A Review . Molecules 2020 , 25 ( 6 ), 1397 10.3390/molecules25061397 . 32204372 PMC7144558

Lee W. H. ; Loo C. Y. ; Young P. M. ; Traini D. ; Mason R. S. ; Rohanizadeh R. Recent advances in curcumin nanoformulation for cancer therapy . Expert Opin Drug Deliv 2014 , 11 ( 8 ), 1183 – 1201 . 10.1517/17425247.2014.916686 . 24857605

Pancholi V. ; Smina T. P. ; Kunnumakkara A. B. ; Maliakel B. ; Krishnakumar I. M. Safety assessment of a highly bioavailable curcumin-galactomannoside complex (CurQfen) in healthy volunteers, with a special reference to the recent hepatotoxic reports of curcumin supplements: A 90-days prospective study . Toxicol Rep 2021 , 8 , 1255 – 1264 . 10.1016/j.toxrep.2021.06.008 . 34195017 PMC8233102

Priyadarsini K. I. The chemistry of curcumin: from extraction to therapeutic agent . Molecules 2014 , 19 ( 12 ), 20091 – 20112 . 10.3390/molecules191220091 . 25470276 PMC6270789

Wang Y. J. ; Pan M. H. ; Cheng A. L. ; Lin L. I. ; Ho Y. S. ; Hsieh C. Y. ; Lin J. K. Stability of curcumin in buffer solutions and characterization of its degradation products . J. Pharm. Biomed Anal 1997 , 15 ( 12 ), 1867 – 1876 . 10.1016/S0731-7085(96)02024-9 . 9278892

Jamwal R. Bioavailable curcumin formulations: A review of pharmacokinetic studies in healthy volunteers . J. Integr Med. 2018 , 16 ( 6 ), 367 – 374 . 10.1016/j.joim.2018.07.001 . 30006023

Kunnumakkara A. B. ; Harsha C. ; Banik K. ; Vikkurthi R. ; Sailo B. L. ; Bordoloi D. ; Gupta S. C. ; Aggarwal B. B. Is curcumin bioavailability a problem in humans: lessons from clinical trials . Expert Opin Drug Metab Toxicol 2019 , 15 ( 9 ), 705 – 733 . 10.1080/17425255.2019.1650914 . 31361978

Imaizumi A. Highly bioavailable curcumin (Theracurmin): Its development and clinical application . PharmaNutrition 2015 , 3 ( 4 ), 123 – 130 . 10.1016/j.phanu.2015.08.002 .

Lao C. D. ; Ruffin M. T. t. ; Normolle D. ; Heath D. D. ; Murray S. I. ; Bailey J. M. ; Boggs M. E. ; Crowell J. ; Rock C. L. ; Brenner D. E. Dose escalation of a curcuminoid formulation . BMC Complement Altern Med. 2006 , 6 , 10 10.1186/1472-6882-6-10 . 16545122 PMC1434783

Sharma R. A. ; Euden S. A. ; Platton S. L. ; Cooke D. N. ; Shafayat A. ; Hewitt H. R. ; Marczylo T. H. ; Morgan B. ; Hemingway D. ; Plummer S. M. ; et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance . Clin. Cancer Res. 2004 , 10 ( 20 ), 6847 – 6854 . 10.1158/1078-0432.CCR-04-0744 . 15501961

Kanai M. ; Yoshimura K. ; Asada M. ; Imaizumi A. ; Suzuki C. ; Matsumoto S. ; Nishimura T. ; Mori Y. ; Masui T. ; Kawaguchi Y. ; et al. A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer . Cancer Chemother Pharmacol 2011 , 68 ( 1 ), 157 – 164 . 10.1007/s00280-010-1470-2 . 20859741

Zheng B. ; McClements D. J. Formulation of More Efficacious Curcumin Delivery Systems Using Colloid Science: Enhanced Solubility, Stability, and Bioavailability . Molecules 2020 , 25 ( 12 ), 2791 10.3390/molecules25122791 . 32560351 PMC7357038

Prasad S. ; Tyagi A. K. ; Aggarwal B. B. Recent developments in delivery, bioavailability, absorption and metabolism of curcumin: the golden pigment from golden spice . Cancer Res. Treat 2014 , 46 ( 1 ), 2 – 18 . 10.4143/crt.2014.46.1.2 . 24520218 PMC3918523

Shoba G. ; Joy D. ; Joseph T. ; Majeed M. ; Rajendran R. ; Srinivas P. S. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers . Planta Med. 1998 , 64 ( 4 ), 353 – 356 . 10.1055/s-2006-957450 . 9619120

Yang K. Y. ; Lin L. C. ; Tseng T. Y. ; Wang S. C. ; Tsai T. H. Oral bioavailability of curcumin in rat and the herbal analysis from Curcuma longa by LC-MS/MS . J. Chromatogr B Analyt Technol. Biomed Life Sci. 2007 , 853 ( 1–2 ), 183 – 189 . 10.1016/j.jchromb.2007.03.010 . 17400527

Pan M. H. ; Huang T. M. ; Lin J. K. Biotransformation of curcumin through reduction and glucuronidation in mice . Drug Metab. Dispos. 1999 , 27 ( 4 ), 486 – 494 . 10101144

Ravindranath V. ; Chandrasekhara N. Metabolism of curcumn-studies with [3H] curcumin . Toxicology 1981 , 22 ( 4 ), 337 – 344 . 10.1016/0300-483X(81)90027-5 . 7342372

Ravindranath V. ; Chandrasekhara N. Absorption and tissue distribution of curcumin in rats . Toxicology 1980 , 16 ( 3 ), 259 – 265 . 10.1016/0300-483X(80)90122-5 . 7423534

Marczylo T. H. ; Verschoyle R. D. ; Cooke D. N. ; Morazzoni P. ; Steward W. P. ; Gescher A. J. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine . Cancer Chemother Pharmacol 2007 , 60 ( 2 ), 171 – 177 . 10.1007/s00280-006-0355-x . 17051370

Garcea G. ; Berry D. P. ; Jones D. J. ; Singh R. ; Dennison A. R. ; Farmer P. B. ; Sharma R. A. ; Steward W. P. ; Gescher A. J. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences . Cancer Epidemiol Biomarkers Prev 2005 , 14 ( 1 ), 120 – 125 . 10.1158/1055-9965.120.14.1 . 15668484

Dhillon N. ; Aggarwal B. B. ; Newman R. A. ; Wolff R. A. ; Kunnumakkara A. B. ; Abbruzzese J. L. ; Ng C. S. ; Badmaev V. ; Kurzrock R. Phase II trial of curcumin in patients with advanced pancreatic cancer . Clin. Cancer Res. 2008 , 14 ( 14 ), 4491 – 4499 . 10.1158/1078-0432.CCR-08-0024 . 18628464

Teiten M. H. ; Dicato M. ; Diederich M. Hybrid curcumin compounds: a new strategy for cancer treatment . Molecules 2014 , 19 ( 12 ), 20839 – 20863 . 10.3390/molecules191220839 . 25514225 PMC6271749

Mirzaei H. ; Shakeri A. ; Rashidi B. ; Jalili A. ; Banikazemi Z. ; Sahebkar A. Phytosomal curcumin: A review of pharmacokinetic, experimental and clinical studies . Biomed Pharmacother 2017 , 85 , 102 – 112 . 10.1016/j.biopha.2016.11.098 . 27930973

DB M. ; Sreedharan S. ; Mahadik K. Role of piperine as an effective bioenhancer in drug absorption . Pharm. Anal Acta 2018 , 9 ( 7 ), 1000591 10.4172/2153-2435.1000591 .

Volak L. P. ; Ghirmai S. ; Cashman J. R. ; Court M. H. Curcuminoids inhibit multiple human cytochromes P450, UDP-glucuronosyltransferase, and sulfotransferase enzymes, whereas piperine is a relatively selective CYP3A4 inhibitor . Drug Metab. Dispos. 2008 , 36 ( 8 ), 1594 – 1605 . 10.1124/dmd.108.020552 . 18480186 PMC2574793

Pal A. ; Sung B. ; Bhanu Prasad B. A. ; Schuber P. T. Jr. ; Prasad S. ; Aggarwal B. B. ; Bornmann W. G. Curcumin glucuronides: assessing the proliferative activity against human cell lines . Bioorg. Med. Chem. 2014 , 22 ( 1 ), 435 – 439 . 10.1016/j.bmc.2013.11.006 . 24280069 PMC4128398

Stohs S. ; Ray S. Issues with human bioavailability determinations of bioactive curcumin . Biomedical Journal of Scientific & Technical Research 2019 , 12 ( 4 ), 9417 – 9419 . 10.26717/BJSTR.2019.12.002289 .

Cardaci T. D. ; Machek S. B. ; Wilburn D. T. ; Hwang P. S. ; Willoughby D. S. Ubiquitin Proteasome System Activity is Suppressed by Curcumin following Exercise-Induced Muscle Damage in Human Skeletal Muscle . J. Am. Coll Nutr 2021 , 40 ( 5 ), 401 – 411 . 10.1080/07315724.2020.1783721 . 32701392

Miranda-Castro S. ; Aidar F. J. ; de Moura S. S. ; Marcucci-Barbosa L. ; Lobo L. F. ; de Assis Dias Martins-Junior F. ; da Silva Filha R. ; Vaz de Castro P. A. S. ; Simoes e Silva A. C. ; da Gloria de Souza D. The Curcumin Supplementation with Piperine Can Influence the Acute Elevation of Exercise-Induced Cytokines: Double-Blind Crossover Study . Biology (Basel) 2022 , 11 ( 4 ), 573 10.3390/biology11040573 . 35453772 PMC9032800

Biswas J. ; Sinha D. ; Mukherjee S. ; Roy S. ; Siddiqi M. ; Roy M. Curcumin protects DNA damage in a chronically arsenic-exposed population of West Bengal . Hum Exp Toxicol 2010 , 29 ( 6 ), 513 – 524 . 10.1177/0960327109359020 . 20056736

Khdair S. A. ; Abdulridha M. K. ; Shafek M. A. The effect of curcumin adjuvant therapy on pulmonary function and levels of interleukin-6 (IL-6) and superoxide dismutase-3 (EC-SOD3) in patients with chronic bronchial asthma . Indonesian Journal of Pharmacy 2021 , 32 , 232 – 240 . 10.22146/ijp.1136 .

Pawar K. S. ; Mastud R. N. ; Pawar S. K. ; Pawar S. S. ; Bhoite R. R. ; Bhoite R. R. ; Kulkarni M. V. ; Deshpande A. R. Oral Curcumin With Piperine as Adjuvant Therapy for the Treatment of COVID-19: A Randomized Clinical Trial . Front Pharmacol 2021 , 12 , 669362 10.3389/fphar.2021.669362 . 34122090 PMC8193734

Askari G. ; Sahebkar A. ; Soleimani D. ; Mahdavi A. ; Rafiee S. ; Majeed M. ; Khorvash F. ; Iraj B. ; Elyasi M. ; Rouhani M. H. ; et al. The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial . Trials 2022 , 23 ( 1 ), 472 10.1186/s13063-022-06375-w . 35668500 PMC9167899

Piyush P. ; Mahajan A. ; Singh K. ; Ghosh S. ; Gupta S. Comparison of therapeutic response of lycopene and curcumin in oral submucous fibrosis: A randomized controlled trial . Oral Dis 2019 , 25 ( 1 ), 73 – 79 . 10.1111/odi.12947 . 30059188

Durgaprasad S. ; Pai C. G. ; Vasanthkumar ; Alvres J. F. ; Namitha S. A pilot study of the antioxidant effect of curcumin in tropical pancreatitis . Indian J. Med. Res. 2005 , 122 ( 4 ), 315 – 318 . 16394323

Panahi Y. ; Khalili N. ; Sahebi E. ; Namazi S. ; Atkin S. L. ; Majeed M. ; Sahebkar A. Curcuminoids Plus Piperine Modulate Adipokines in Type 2 Diabetes Mellitus . Curr. Clin Pharmacol 2018 , 12 ( 4 ), 253 – 258 . 10.2174/1574884713666180104095641 . 29299989

Hemmati A. A. ; Rajaee E. ; Houshmand G. ; Fakhroddin M. ; Dargahi-MalAmir M. ; Hesam S. ; Maram N. Study the effects of anti-inflammatory curcumex capsules containing three plants (ginger, curcumin and black pepper) in patients with active rheumatoid arthritis . IIOAB Journal 2016 , 7 ( Suppl 5 ), 389 – 392 .

Hatab H. M. ; Abdel Hamid F. F. ; Soliman A. F. ; Al-Shafie T. A. ; Ismail Y. M. ; El-Houseini M. E. A combined treatment of curcumin, piperine, and taurine alters the circulating levels of IL-10 and miR-21 in hepatocellular carcinoma patients: a pilot study . J. Gastrointest Oncol 2019 , 10 ( 4 ), 766 – 776 . 10.21037/jgo.2019.03.07 . 31392057 PMC6657326

O’Rawe M. ; Wickremesekera A. C. ; Pandey R. ; Young D. ; Sim D. ; FitzJohn T. ; Burgess C. ; Kaye A. H. ; Tan S. T. Treatment of glioblastoma with re-purposed renin-angiotensin system modulators: Results of a phase I clinical trial . J. Clin Neurosci 2022 , 95 , 48 – 54 . 10.1016/j.jocn.2021.11.023 . 34929651

Stancioiu F. ; Mihai D. ; Papadakis G. Z. ; Tsatsakis A. ; Spandidos D. A. ; Badiu C. Treatment for benign thyroid nodules with a combination of natural extracts . Mol. Med. Rep 2019 , 20 ( 3 ), 2332 – 2338 . 10.3892/mmr.2019.10453 . 31322200 PMC6691239

Portincasa P. ; Bonfrate L. ; Scribano M. L. ; Kohn A. ; Caporaso N. ; Festi D. ; Campanale M. C. ; Di Rienzo T. ; Guarino M. ; Taddia M. ; et al. Curcumin and Fennel Essential Oil Improve Symptoms and Quality of Life in Patients with Irritable Bowel Syndrome . J. Gastrointestin Liver Dis 2020 , 25 ( 2 ), 151 – 157 . 10.15403/jgld.2014.1121.252.ccm . 27308645

Cruz-Correa M. ; Shoskes D. A. ; Sanchez P. ; Zhao R. ; Hylind L. M. ; Wexner S. D. ; Giardiello F. M. Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis . Clin Gastroenterol Hepatol 2006 , 4 ( 8 ), 1035 – 1038 . 10.1016/j.cgh.2006.03.020 . 16757216

Di Mario F. ; Cavallaro L. G. ; Nouvenne A. ; Stefani N. ; Cavestro G. M. ; Iori V. ; Maino M. ; Comparato G. ; Fanigliulo L. ; Morana E. ; et al. A curcumin-based 1-week triple therapy for eradication of Helicobacter pylori infection: something to learn from failure? . Helicobacter 2007 , 12 ( 3 ), 238 – 243 . 10.1111/j.1523-5378.2007.00497.x . 17493004

Morgia G. ; Russo G. I. ; Urzi D. ; Privitera S. ; Castelli T. ; Favilla V. ; Cimino S. A phase II, randomized, single-blinded, placebo-controlled clinical trial on the efficacy of Curcumina and Calendula suppositories for the treatment of patients with chronic prostatitis/chronic pelvic pain syndrome type III . Arch Ital Urol Androl 2017 , 89 ( 2 ), 110 – 113 . 10.4081/aiua.2017.2.110 . 28679180

Miodownik C. ; Lerner V. ; Kudkaeva N. ; Lerner P. P. ; Pashinian A. ; Bersudsky Y. ; Eliyahu R. ; Kreinin A. ; Bergman J. Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study . Clin Neuropharmacol 2019 , 42 ( 4 ), 117 – 122 . 10.1097/WNF.0000000000000344 . 31045590

Mustafa M. W. ; Ungphaiboon S. ; Phadoongsombut N. ; Pangsomboon K. ; Chelae S. ; Mahattanadul S. Effectiveness of an Alcohol-Free Chitosan-Curcuminoid Mouthwash Compared with Chlorhexidine Mouthwash in Denture Stomatitis Treatment: A Randomized Trial . J. Altern Complement Med. 2019 , 25 ( 5 ), 552 – 558 . 10.1089/acm.2018.0459 . 30758216

Anusha D. ; Chaly P. E. ; Junaid M. ; Nijesh J. E. ; Shivashankar K. ; Sivasamy S. Efficacy of a mouthwash containing essential oils and curcumin as an adjunct to nonsurgical periodontal therapy among rheumatoid arthritis patients with chronic periodontitis: A randomized controlled trial . Indian J. Dent Res. 2019 , 30 ( 4 ), 506 – 511 . 10.4103/ijdr.IJDR_662_17 . 31745043

Panahi Y. ; Ghanei M. ; Bashiri S. ; Hajihashemi A. ; Sahebkar A. Short-term Curcuminoid Supplementation for Chronic Pulmonary Complications due to Sulfur Mustard Intoxication: Positive Results of a Randomized Double-blind Placebo-controlled Trial . Drug Res. (Stuttg) 2015 , 65 ( 11 ), 567 – 573 . 10.1055/s-0034-1389986 . 25268878

Panahi Y. ; Khalili N. ; Sahebi E. ; Namazi S. ; Simental-Mendia L. E. ; Majeed M. ; Sahebkar A. Effects of Curcuminoids Plus Piperine on Glycemic, Hepatic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Placebo-Controlled Trial . Drug Res. (Stuttg) 2018 , 68 ( 7 ), 403 – 409 . 10.1055/s-0044-101752 . 29458218

Panahi Y. ; Alishiri G. H. ; Parvin S. ; Sahebkar A. Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial . J. Diet Suppl 2016 , 13 ( 2 ), 209 – 220 . 10.3109/19390211.2015.1008611 . 25688638

Panahi Y. ; Khalili N. ; Hosseini M. S. ; Abbasinazari M. ; Sahebkar A. Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial . Complement Ther Med. 2014 , 22 ( 5 ), 851 – 857 . 10.1016/j.ctim.2014.07.006 . 25440375

Panahi Y. ; Hosseini M. S. ; Khalili N. ; Naimi E. ; Majeed M. ; Sahebkar A. Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis . Clin Nutr 2015 , 34 ( 6 ), 1101 – 1108 . 10.1016/j.clnu.2014.12.019 . 25618800

Panahi Y. ; Hosseini M. S. ; Khalili N. ; Naimi E. ; Simental-Mendía L. E. ; Majeed M. ; Sahebkar A. Effects of curcumin on serum cytokine concentrations in subjects with metabolic syndrome: A post-hoc analysis of a randomized controlled trial . Biomedicine & pharmacotherapy 2016 , 82 , 578 – 582 . 10.1016/j.biopha.2016.05.037 . 27470399

Panahi Y. ; Hosseini M. S. ; Khalili N. ; Naimi E. ; Soflaei S. S. ; Majeed M. ; Sahebkar A. Effects of supplementation with curcumin on serum adipokine concentrations: A randomized controlled trial . Nutrition 2016 , 32 ( 10 ), 1116 – 1122 . 10.1016/j.nut.2016.03.018 . 27297718

Panahi Y. ; Valizadegan G. ; Ahamdi N. ; Ganjali S. ; Majeed M. ; Sahebkar A. Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial . J. Cell Biochem 2019 , 120 ( 9 ), 15989 – 15996 . 10.1002/jcb.28877 . 31168845

Saberi-Karimian M. ; Keshvari M. ; Ghayour-Mobarhan M. ; Salehizadeh L. ; Rahmani S. ; Behnam B. ; Jamialahmadi T. ; Asgary S. ; Sahebkar A. Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial . Complement Ther Med. 2020 , 49 , 102322 10.1016/j.ctim.2020.102322 . 32147075

Mohammadi A. ; Sahebkar A. ; Iranshahi M. ; Amini M. ; Khojasteh R. ; Ghayour-Mobarhan M. ; Ferns G. A. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial . Phytother Res. 2013 , 27 ( 3 ), 374 – 379 . 10.1002/ptr.4715 . 22610853

Panahi Y. ; Sahebkar A. ; Amiri M. ; Davoudi S. M. ; Beiraghdar F. ; Hoseininejad S. L. ; Kolivand M. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: results of a randomised, double-blind, placebo-controlled trial . Br. J. Nutr. 2012 , 108 ( 7 ), 1272 – 1279 . 10.1017/S0007114511006544 . 22099425

Shadnoush M. ; Zahedi H. ; Norouzy A. ; Sahebkar A. ; Sadeghi O. ; Najafi A. ; Hosseini S. ; Qorbani M. ; Ahmadi A. ; Ardehali S. H. ; et al. Effects of supplementation with curcuminoids on serum adipokines in critically ill patients: a randomized double-blind placebo-controlled trial . Phytother Res. 2020 , 34 ( 12 ), 3180 – 3188 . 10.1002/ptr.6749 . 32542818

Zahedi H. ; Hosseinzadeh-Attar M. J. ; Shadnoush M. ; Sahebkar A. ; Barkhidarian B. ; Sadeghi O. ; Najafi A. ; Hosseini S. ; Qorbani M. ; Ahmadi A. ; et al. Effects of curcuminoids on inflammatory and oxidative stress biomarkers and clinical outcomes in critically ill patients: A randomized double-blind placebo-controlled trial . Phytother Res. 2021 , 35 ( 8 ), 4605 – 4615 . 10.1002/ptr.7179 . 34080237

Arabnezhad L. ; Mohammadifard M. ; Rahmani L. ; Majidi Z. ; Ferns G. A. ; Bahrami A. Effects of curcumin supplementation on vitamin D levels in women with premenstrual syndrome and dysmenorrhea: a randomized controlled study . BMC Complement Med. Ther 2022 , 22 ( 1 ), 19 10.1186/s12906-022-03515-2 . 35065636 PMC8784001

Bahrami A. ; Zarban A. ; Rezapour H. ; Agha Amini Fashami A. ; Ferns G. A. Effects of curcumin on menstrual pattern, premenstrual syndrome, and dysmenorrhea: A triple-blind, placebo-controlled clinical trial . Phytother Res. 2021 , 35 ( 12 ), 6954 – 6962 . 10.1002/ptr.7314 . 34708460

Panahi Y. ; Khalili N. ; Sahebi E. ; Namazi S. ; Karimian M. S. ; Majeed M. ; Sahebkar A. Antioxidant effects of curcuminoids in patients with type 2 diabetes mellitus: a randomized controlled trial . Inflammopharmacology 2017 , 25 ( 1 ), 25 – 31 . 10.1007/s10787-016-0301-4 . 27928704

Sahebkar A. ; Mohammadi A. ; Atabati A. ; Rahiman S. ; Tavallaie S. ; Iranshahi M. ; Akhlaghi S. ; Ferns G. A. ; Ghayour-Mobarhan M. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals . Phytother Res. 2013 , 27 ( 12 ), 1883 – 1888 . 10.1002/ptr.4952 . 23494802

Mohajer A. ; Ghayour-Mobarhan M. ; Parizadeh S. M. R. ; Tavallaie S. ; Rajabian M. ; Sahebkar A. Effects of supplementation with curcuminoids on serum copper and zinc concentrations and superoxide dismutase enzyme activity in obese subjects . Trace Elem Electrolytes 2015 , 32 , 16 – 21 . 10.5414/TEX01363 .

Ganjali S. ; Sahebkar A. ; Mahdipour E. ; Jamialahmadi K. ; Torabi S. ; Akhlaghi S. ; Ferns G. ; Parizadeh S. M. ; Ghayour-Mobarhan M. Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial . ScientificWorldJournal 2014 , 2014 , 898361 10.1155/2014/898361 . 24678280 PMC3942342

Rahimnia A. R. ; Panahi Y. ; Alishiri G. ; Sharafi M. ; Sahebkar A. Impact of Supplementation with Curcuminoids on Systemic Inflammation in Patients with Knee Osteoarthritis: Findings from a Randomized Double-Blind Placebo-Controlled Trial . Drug Res. (Stuttg) 2015 , 65 ( 10 ), 521 – 525 . 10.1055/s-0034-1384536 . 25050518

Panahi Y. ; Sahebkar A. ; Parvin S. ; Saadat A. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications . Ann. Clin Biochem 2012 , 49 , 580 – 588 . 10.1258/acb.2012.012040 . 23038702

Panahi Y. ; Ghanei M. ; Hajhashemi A. ; Sahebkar A. Effects of Curcuminoids-Piperine Combination on Systemic Oxidative Stress, Clinical Symptoms and Quality of Life in Subjects with Chronic Pulmonary Complications Due to Sulfur Mustard: A Randomized Controlled Trial . J. Diet Suppl 2016 , 13 ( 1 ), 93 – 105 . 10.3109/19390211.2014.952865 . 25171552

Panahi Y. ; Khalili N. ; Sahebi E. ; Namazi S. ; Reiner Z. ; Majeed M. ; Sahebkar A. Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial . Complement Ther Med. 2017 , 33 , 1 – 5 . 10.1016/j.ctim.2017.05.006 . 28735818

Mirhafez S. R. ; Farimani A. R. ; Gholami A. ; Hooshmand E. ; Tavallaie S. ; Nobakht M. Gh B. F. The effect of curcumin with piperine supplementation on pro-oxidant and antioxidant balance in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial . Drug Metab Pers Ther 2019 , 34 ( 2 ), 20180040 10.1515/dmpt-2018-0040 . 31145689

Rai A. ; Kaur M. ; Gombra V. ; Hasan S. ; Kumar N. Comparative evaluation of curcumin and antioxidants in the management of oral submucous fibrosis . J. Investig Clin Dent 2019 , 10 ( 4 ), e12464 10.1111/jicd.12464 . 31605442

Sharma N. ; Jain A. ; Bahudar S. ; Oberoi S. S. Efficacy of Curcumin and Piperine as Antioxidant Adjuvant to Intralesional Dexamethasone Injection for Management of Oral Submucous Fibrosis: A Clinical Trial . Journal of Orofacial Sciences 2021 , 13 ( 2 ), 129 10.4103/jofs.jofs_218_21 .

Volak L. P. ; Hanley M. J. ; Masse G. ; Hazarika S. ; Harmatz J. S. ; Badmaev V. ; Majeed M. ; Greenblatt D. J. ; Court M. H. Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers . Br. J. Clin. Pharmacol. 2013 , 75 ( 2 ), 450 – 462 . 10.1111/j.1365-2125.2012.04364.x . 22725836 PMC3579260

Sunagawa Y. ; Hirano S. ; Katanasaka Y. ; Miyazaki Y. ; Funamoto M. ; Okamura N. ; Hojo Y. ; Suzuki H. ; Doi O. ; Yokoji T. ; et al. Colloidal submicron-particle curcumin exhibits high absorption efficiency-a double-blind, 3-way crossover study . J. Nutr Sci. Vitaminol (Tokyo) 2015 , 61 ( 1 ), 37 – 44 . 10.3177/jnsv.61.37 . 25994138

Antony B. ; Merina B. ; Iyer V. S. ; Judy N. ; Lennertz K. ; Joyal S. A Pilot Cross-Over Study to Evaluate Human Oral Bioavailability of BCM-95CG (Biocurcumax), A Novel Bioenhanced Preparation of Curcumin . Indian J. Pharm. Sci. 2008 , 70 ( 4 ), 445 – 449 . 10.4103/0250-474X.44591 . 20046768 PMC2792534

Santosa D. ; Suharti C. ; Riwanto I. ; Dharmana E. ; Pangarsa E. A. ; Setiawan B. ; Suyono S. ; Tobing M. L. ; Suhartono S. ; Hadisapurto S. Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial . Caspian J. Intern Med. 2022 , 13 ( 2 ), 375 – 384 . 10.22088/cjim.13.2.9 . 35919637 PMC9301229

Petracca M. ; Quarantelli M. ; Moccia M. ; Vacca G. ; Satelliti B. ; D’Ambrosio G. ; Carotenuto A. ; Ragucci M. ; Assogna F. ; Capacchione A. ; et al. ProspeCtive study to evaluate efficacy, safety and tOlerability of dietary supplemeNT of Curcumin (BCM95) in subjects with Active relapsing MultIple Sclerosis treated with subcutaNeous Interferon beta 1a 44 mcg TIW (CONTAIN): A randomized, controlled trial . Mult Scler Relat Disord 2021 , 56 , 103274 10.1016/j.msard.2021.103274 . 34583214

Saadati S. ; Sadeghi A. ; Mansour A. ; Yari Z. ; Poustchi H. ; Hedayati M. ; Hatami B. ; Hekmatdoost A. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo controlled clinical trial . BMC Gastroenterol 2019 , 19 ( 1 ), 133 10.1186/s12876-019-1055-4 . 31345163 PMC6659284

Karandish M. ; Mozaffari-Khosravi H. ; Mohammadi S. M. ; Cheraghian B. ; Azhdari M. Curcumin and zinc co-supplementation along with a loss-weight diet can improve lipid profiles in subjects with prediabetes: a multi-arm, parallel-group, randomized, double-blind placebo-controlled phase 2 clinical trial . Diabetol Metab Syndr 2022 , 14 ( 1 ), 22 10.1186/s13098-022-00792-2 . 35090529 PMC8796182

Cerletti C. ; Colucci M. ; Storto M. ; Semeraro F. ; Ammollo C. T. ; Incampo F. ; Costanzo S. ; De Bartolomeo G. ; Portincasa P. ; Barone M. ; et al. Randomised trial of chronic supplementation with a nutraceutical mixture in subjects with non-alcoholic fatty liver disease . Br. J. Nutr. 2020 , 123 ( 2 ), 190 – 197 . 10.1017/S0007114519002484 . 31554528

Sterzi S. ; Giordani L. ; Morrone M. ; Lena E. ; Magrone G. ; Scarpini C. ; Milighetti S. ; Pellicciari L. ; Bravi M. ; Panni I. ; et al. The efficacy and safety of a combination of glucosamine hydrochloride, chondroitin sulfate and bio-curcumin with exercise in the treatment of knee osteoarthritis: a randomized, double-blind, placebo-controlled study . Eur. J. Phys. Rehabil Med. 2016 , 52 ( 3 ), 321 – 330 . 26937646

Haroyan A. ; Mukuchyan V. ; Mkrtchyan N. ; Minasyan N. ; Gasparyan S. ; Sargsyan A. ; Narimanyan M. ; Hovhannisyan A. Efficacy and safety of curcumin and its combination with boswellic acid in osteoarthritis: a comparative, randomized, double-blind, placebo-controlled study . BMC Complement Altern Med. 2018 , 18 ( 1 ), 7 10.1186/s12906-017-2062-z . 29316908 PMC5761198

Al-Askar M. ; AlMubarak A. M. ; Alqutub M. N. ; Mokeem S. ; Javed F. ; Vohra F. ; Abduljabbar T. Analgesic Efficacy of Curcuma longa (Curcumin) after Surgical Periodontal Therapy . Oral Health Prev Dent 2022 , 20 ( 1 ), 19 – 26 . 10.3290/j.ohpd.b2572979 . 35049249 PMC11640709

Karandish M. ; Mozaffari-Khosravi H. ; Mohammadi S. M. ; Cheraghian B. ; Azhdari M. The effect of curcumin and zinc co-supplementation on glycemic parameters in overweight or obese prediabetic subjects: A phase 2 randomized, placebo-controlled trial with a multi-arm, parallel-group design . Phytother Res. 2021 , 35 ( 8 ), 4377 – 4387 . 10.1002/ptr.7136 . 33893671

Hellou E. ; Mohsin J. ; Elemy A. ; Hakim F. ; Mustafa-Hellou M. ; Hamoud S. Effect of ArtemiC in patients with COVID-19: A Phase II prospective study . J. Cell Mol. Med. 2022 , 26 ( 11 ), 3281 – 3289 . 10.1111/jcmm.17337 . 35587574 PMC9170814

Boutry-Regard C. ; Vinyes-Pares G. ; Breuille D. ; Moritani T. Supplementation with Whey Protein, Omega-3 Fatty Acids and Polyphenols Combined with Electrical Muscle Stimulation Increases Muscle Strength in Elderly Adults with Limited Mobility: A Randomized Controlled Trial . Nutrients 2020 , 12 ( 6 ), 1866 10.3390/nu12061866 . 32585837 PMC7353259

Saghatelyan T. ; Tananyan A. ; Janoyan N. ; Tadevosyan A. ; Petrosyan H. ; Hovhannisyan A. ; Hayrapetyan L. ; Arustamyan M. ; Arnhold J. ; Rotmann A. R. ; et al. Efficacy and safety of curcumin in combination with paclitaxel in patients with advanced, metastatic breast cancer: A comparative, randomized, double-blind, placebo-controlled clinical trial . Phytomedicine 2020 , 70 , 153218 10.1016/j.phymed.2020.153218 . 32335356

Shapira S. ; Leshno A. ; Katz D. ; Maharshak N. ; Hevroni G. ; Jean-David M. ; Kraus S. ; Galazan L. ; Aroch I. ; Kazanov D. ; et al. Of mice and men: a novel dietary supplement for the treatment of ulcerative colitis . Therap Adv. Gastroenterol 2018 , 11 , 1756283X1774186 10.1177/1756283X17741864 . PMC5784533 29383023

Elad S. ; Meidan I. ; Sellam G. ; Simaan S. ; Zeevi I. ; Waldman E. ; Weintraub M. ; Revel-Vilk S. Topical curcumin for the prevention of oral mucositis in pediatric patients: case series . Altern Ther Health Med. 2013 , 19 ( 3 ), 21 – 24 . 23709456

Rahmani S. ; Asgary S. ; Askari G. ; Keshvari M. ; Hatamipour M. ; Feizi A. ; Sahebkar A. Treatment of Non-alcoholic Fatty Liver Disease with Curcumin: A Randomized Placebo-controlled Trial . Phytother Res. 2016 , 30 ( 9 ), 1540 – 1548 . 10.1002/ptr.5659 . 27270872

Takahashi M. ; Suzuki K. ; Kim H. K. ; Otsuka Y. ; Imaizumi A. ; Miyashita M. ; Sakamoto S. Effects of curcumin supplementation on exercise-induced oxidative stress in humans . Int. J. Sports Med. 2014 , 35 ( 6 ), 469 – 475 . 10.1055/s-0033-1357185 . 24165958

Varma K. ; Amalraj A. ; Divya C. ; Gopi S. The Efficacy of the Novel Bioavailable Curcumin (Cureit) in the Management of Sarcopenia in Healthy Elderly Subjects: A Randomized, Placebo-Controlled, Double-Blind Clinical Study . J. Med. Food 2021 , 24 ( 1 ), 40 – 49 . 10.1089/jmf.2020.4778 . 33290142

Gopi S. ; Jacob J. ; Varma K. ; Jude S. ; Amalraj A. ; Arundhathy C. A. ; George R. ; Sreeraj T. R. ; Divya C. ; Kunnumakkara A. B. ; et al. Comparative Oral Absorption of Curcumin in a Natural Turmeric Matrix with Two Other Curcumin Formulations: An Open-label Parallel-arm Study . Phytother Res. 2017 , 31 ( 12 ), 1883 – 1891 . 10.1002/ptr.5931 . 29027274

Amalraj A. ; Divya C. ; Gopi S. The Effects of Bioavailable Curcumin (Cureit) on Delayed Onset Muscle Soreness Induced By Eccentric Continuous Exercise: A Randomized, Placebo-Controlled, Double-Blind Clinical Study . J. Med. Food 2020 , 23 ( 5 ), 545 – 553 . 10.1089/jmf.2019.4533 . 32109179

Purpura M. ; Lowery R. P. ; Wilson J. M. ; Mannan H. ; Munch G. ; Razmovski-Naumovski V. Analysis of different innovative formulations of curcumin for improved relative oral bioavailability in human subjects . Eur. J. Nutr 2018 , 57 ( 3 ), 929 – 938 . 10.1007/s00394-016-1376-9 . 28204880 PMC5861163

Amalraj A. ; Varma K. ; Jacob J. ; Divya C. ; Kunnumakkara A. B. ; Stohs S. J. ; Gopi S. A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study . J. Med. Food 2017 , 20 ( 10 ), 1022 – 1030 . 10.1089/jmf.2017.3930 . 28850308

Adibian M. ; Hodaei H. ; Nikpayam O. ; Sohrab G. ; Hekmatdoost A. ; Hedayati M. The effects of curcumin supplementation on high-sensitivity C-reactive protein, serum adiponectin, and lipid profile in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled trial . Phytother Res. 2019 , 33 ( 5 ), 1374 – 1383 . 10.1002/ptr.6328 . 30864188

Hodaei H. ; Adibian M. ; Nikpayam O. ; Hedayati M. ; Sohrab G. The effect of curcumin supplementation on anthropometric indices, insulin resistance and oxidative stress in patients with type 2 diabetes: a randomized, double-blind clinical trial . Diabetol Metab Syndr 2019 , 11 , 41 10.1186/s13098-019-0437-7 . 31149032 PMC6537430

Heng M. C. ; Song M. K. ; Harker J. ; Heng M. K. Drug-induced suppression of phosphorylase kinase activity correlates with resolution of psoriasis as assessed by clinical, histological and immunohistochemical parameters . Br J. Dermatol 2000 , 143 ( 5 ), 937 – 949 . 10.1046/j.1365-2133.2000.03767.x . 11069500

Nerkar Rajbhoj A. ; Kulkarni T. M. ; Shete A. ; Shete M. ; Gore R. ; Sapkal R. A Comparative Study to Evaluate Efficacy of Curcumin and Aloe Vera Gel along with Oral Physiotherapy in the Management of Oral Submucous Fibrosis: A Randomized Clinical Trial . Asian Pac J. Cancer Prev 2021 , 22 ( S1 ), 107 – 112 . 10.31557/APJCP.2021.22.S1.107 . 33576219

Chandrashekar A. ; Annigeri R. G. ; Va U. ; Thimmasetty J. A clinicobiochemical evaluation of curcumin as gel and as buccal mucoadhesive patches in the management of oral submucous fibrosis . Oral Surg Oral Med. Oral Pathol Oral Radiol 2021 , 131 ( 4 ), 428 – 434 . 10.1016/j.oooo.2020.12.020 . 33509742

Mikirova N. A. ; Kesari S. ; Ichim T. E. ; Riordan N. H. Effect of Infla-Kine supplementation on the gene expression of inflammatory markers in peripheral mononuclear cells and on C-reactive protein in blood . J. Transl Med. 2017 , 15 ( 1 ), 213 10.1186/s12967-017-1315-4 . 29058588 PMC5651612

Zupi E. ; Lazzeri L. ; Centini G. Endometriosis and pain: postsurgical alternative treatment in patients desiring pregnancy . Journal of Endometriosis and Pelvic Pain Disorders 2015 , 7 ( 3 ), 95 – 99 . 10.5301/je.5000226 .

Cosentino V. ; Fratter A. ; Cosentino M. Anti-inflammatory effects exerted by Killox(R), an innovative formulation of food supplement with curcumin, in urology . Eur. Rev. Med. Pharmacol Sci. 2016 , 20 ( 7 ), 1390 – 1398 . 27097964

Radkar P. ; Lakshmanan P. S. ; Mary J. J. ; Chaudhary S. ; Durairaj S. K. A Novel Multi-Ingredient Supplement Reduces Inflammation of the Eye and Improves Production and Quality of Tears in Humans . Ophthalmol Ther 2021 , 10 ( 3 ), 581 – 599 . 10.1007/s40123-021-00357-y . 34129210 PMC8319251

Dominiak K. ; McKinney J. ; Heilbrun L. K. ; Sarkar F. H. Critical need for clinical trials: an example of a pilot human intervention trial of a mixture of natural agents protecting lymphocytes against TNF-alpha induced activation of NF-kappaB . Pharm. Res. 2010 , 27 ( 6 ), 1061 – 1065 . 10.1007/s11095-010-0113-y . 20372995 PMC3883052

Maes M. ; Leunis J. C. Attenuation of autoimmune responses to oxidative specific epitopes, but not nitroso-adducts, is associated with a better clinical outcome in Myalgic Encephalomyelitis/chronic fatigue syndrome . Neuro Endocrinol Lett. 2014 , 35 ( 7 ), 577 – 585 . 25617880

Martinez N. ; Herrera M. ; Frias L. ; Provencio M. ; Perez-Carrion R. ; Diaz V. ; Morse M. ; Crespo M. C. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study . Clin Transl Oncol 2019 , 21 ( 4 ), 489 – 498 . 10.1007/s12094-018-1950-0 . 30293230

Derosa G. ; D’Angelo A. ; Vanelli A. ; Maffioli P. An Evaluation of a Nutraceutical with Berberine, Curcumin, Inositol, Banaba and Chromium Picolinate in Patients with Fasting Dysglycemia . Diabetes Metab Syndr Obes 2020 , 13 , 653 – 661 . 10.2147/DMSO.S232791 . 32184644 PMC7060772

Asada K. ; Ohara T. ; Muroyama K. ; Yamamoto Y. ; Murosaki S. Effects of hot water extract of Curcuma longa on human epidermal keratinocytes in vitro and skin conditions in healthy participants: A randomized, double-blind, placebo-controlled trial . J. Cosmet Dermatol 2019 , 18 ( 6 ), 1866 – 1874 . 10.1111/jocd.12890 . 30809971

Ablon G. ; Kogan S. A Six-Month, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of a Nutraceutical Supplement for Promoting Hair Growth in Women With Self-Perceived Thinning Hair . J. Drugs Dermatol 2018 , 17 ( 5 ), 558 – 565 . 29742189

Amalraj A. ; Varma K. ; Jacob J. ; Kuttappan S. Efficacy and safety of a gut health product (Actbiome) prepared by incorporation of asafoetida-curcumin complex onto the turmeric dietary fiber in the management of gut health and intestinal microflora in healthy subjects: A randomized, double-blind, placebo controlled study . Bioactive Carbohydrates and Dietary Fibre 2021 , 26 , 100280 10.1016/j.bcdf.2021.100280 .

Stohs S. J. ; Ji J. ; Bucci L. R. ; Preuss H. G. A Comparative Pharmacokinetic Assessment of a Novel Highly Bioavailable Curcumin Formulation with 95% Curcumin: A Randomized, Double-Blind, Crossover Study . J. Am. Coll Nutr 2018 , 37 ( 1 ), 51 – 59 . 10.1080/07315724.2017.1358118 . 29043927

Birudaraju D. ; Cherukuri L. ; Kinninger A. ; Chaganti B. T. ; Shaikh K. ; Hamal S. ; Flores F. ; Roy S. K. ; Budoff M. J. A combined effect of Cavacurcumin, Eicosapentaenoic acid (Omega-3s), Astaxanthin and Gamma -linoleic acid (Omega-6) (CEAG) in healthy volunteers- a randomized, double-blind, placebo-controlled study . Clin Nutr ESPEN 2020 , 35 , 174 – 179 . 10.1016/j.clnesp.2019.09.011 . 31987113

Jager R. ; Lowery R. P. ; Calvanese A. V. ; Joy J. M. ; Purpura M. ; Wilson J. M. Comparative absorption of curcumin formulations . Nutr J. 2014 , 13 , 11 10.1186/1475-2891-13-11 . 24461029 PMC3918227

Parravano M. ; Allegrini D. ; Carnevali A. ; Costanzo E. ; Giannaccare G. ; Giorno P. ; Scorcia V. ; Spedicato G. A. ; Varano M. ; Romano M. R. Effectiveness of a Hydrophilic Curcumin-Based Formulation in Coadjuvating the Therapeutic Effect of Intravitreal Dexamethasone in Subjects With Diabetic Macular Edema . Front Pharmacol 2022 , 12 , 726104 10.3389/fphar.2021.726104 . 35058773 PMC8763693

Cicero A. F. G. ; Sahebkar A. ; Fogacci F. ; Bove M. ; Giovannini M. ; Borghi C. Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial . Eur. J. Nutr 2020 , 59 ( 2 ), 477 – 483 . 10.1007/s00394-019-01916-7 . 30796508 PMC7058573

Kocher A. ; Bohnert L. ; Schiborr C. ; Frank J. Highly bioavailable micellar curcuminoids accumulate in blood, are safe and do not reduce blood lipids and inflammation markers in moderately hyperlipidemic individuals . Mol. Nutr Food Res. 2016 , 60 ( 7 ), 1555 – 1563 . 10.1002/mnfr.201501034 . 26909743

Schiborr C. ; Kocher A. ; Behnam D. ; Jandasek J. ; Toelstede S. ; Frank J. The oral bioavailability of curcumin from micronized powder and liquid micelles is significantly increased in healthy humans and differs between sexes . Mol. Nutr Food Res. 2014 , 58 ( 3 ), 516 – 527 . 10.1002/mnfr.201300724 . 24402825

Dutzmann S. ; Schiborr C. ; Kocher A. ; Pilatus U. ; Hattingen E. ; Weissenberger J. ; Gessler F. ; Quick-Weller J. ; Franz K. ; Seifert V. ; et al. Intratumoral Concentrations and Effects of Orally Administered Micellar Curcuminoids in Glioblastoma Patients . Nutr Cancer 2016 , 68 ( 6 ), 943 – 948 . 10.1080/01635581.2016.1187281 . 27340742

Aslanabadi N. ; Entezari-Maleki T. ; Rezaee H. ; Jafarzadeh H. R. ; Vahedpour R. Curcumin for the prevention of myocardial injury following elective percutaneous coronary intervention; a pilot randomized clinical trial . Eur. J. Pharmacol. 2019 , 858 , 172471 10.1016/j.ejphar.2019.172471 . 31228455

Sitzia C. ; Meregalli M. ; Belicchi M. ; Farini A. ; Arosio M. ; Bestetti D. ; Villa C. ; Valenti L. ; Brambilla P. ; Torrente Y. Preliminary Evidences of Safety and Efficacy of Flavonoids- and Omega 3-Based Compound for Muscular Dystrophies Treatment: A Randomized Double-Blind Placebo Controlled Pilot Clinical Trial . Front Neurol 2019 , 10 , 755 10.3389/fneur.2019.00755 . 31396142 PMC6664031

Henrotin Y. ; Gharbi M. ; Dierckxsens Y. ; Priem F. ; Marty M. ; Seidel L. ; Albert A. ; Heuse E. ; Bonnet V. ; Castermans C. Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial . BMC Complement Altern Med. 2014 , 14 , 159 10.1186/1472-6882-14-159 . 24886572 PMC4032499

Liu X. ; Robbins S. ; Eyles J. ; Fedorova T. ; Virk S. ; Deveza L. A. ; McLachlan A. J. ; Hunter D. J. Efficacy and safety of a supplement combination on hand pain among people with symptomatic hand osteoarthritis an internet-based, randomised clinical trial the RADIANT study . Osteoarthritis Cartilage 2021 , 29 ( 5 ), 667 – 677 . 10.1016/j.joca.2021.01.011 . 33617972

Tiekou Lorinczova H. ; Begum G. ; Temouri L. ; Renshaw D. ; Zariwala M. G. Co-Administration of Iron and Bioavailable Curcumin Reduces Levels of Systemic Markers of Inflammation and Oxidative Stress in a Placebo-Controlled Randomised Study . Nutrients 2022 , 14 ( 3 ), 712 10.3390/nu14030712 . 35277071 PMC8838381

Mallard A. R. ; Briskey D. ; Richards A. ; Rao A. Curcumin Improves Delayed Onset Muscle Soreness and Postexercise Lactate Accumulation . J. Diet Suppl 2021 , 18 ( 5 ), 531 – 542 . 10.1080/19390211.2020.1796885 . 32705925

Greil R. ; Greil-Ressler S. ; Weiss L. ; Schonlieb C. ; Magnes T. ; Radl B. ; Bolger G. T. ; Vcelar B. ; Sordillo P. P. A phase 1 dose-escalation study on the safety, tolerability and activity of liposomal curcumin (Lipocurc()) in patients with locally advanced or metastatic cancer . Cancer Chemother Pharmacol 2018 , 82 ( 4 ), 695 – 706 . 10.1007/s00280-018-3654-0 . 30074076 PMC6132848

Mohammadi A. ; Sadeghnia H. R. ; Saberi-Karimian M. ; Safarian H. ; Ferns G. A. ; Ghayour-Mobarhan M. ; Sahebkar A. Effects of Curcumin on Serum Vitamin E Concentrations in Individuals with Metabolic Syndrome . Phytother Res. 2017 , 31 ( 4 ), 657 – 662 . 10.1002/ptr.5779 . 28198120

Tonnesen H. H. ; Masson M. ; Loftsson T. Studies of curcumin and curcuminoids. XXVII. Cyclodextrin complexation: solubility, chemical and photochemical stability . Int. J. Pharm. 2002 , 244 ( 1–2 ), 127 – 135 . 10.1016/S0378-5173(02)00323-X . 12204572

Ma Z. ; Haddadi A. ; Molavi O. ; Lavasanifar A. ; Lai R. ; Samuel J. Micelles of poly(ethylene oxide)-b-poly(epsilon-caprolactone) as vehicles for the solubilization, stabilization, and controlled delivery of curcumin . J. Biomed Mater. Res. 2008 , 86A ( 2 ), 300 – 310 . 10.1002/jbm.a.31584 . 17957721

Cuomo J. ; Appendino G. ; Dern A. S. ; Schneider E. ; McKinnon T. P. ; Brown M. J. ; Togni S. ; Dixon B. M. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation . J. Nat. Prod 2011 , 74 ( 4 ), 664 – 669 . 10.1021/np1007262 . 21413691

Asher G. N. ; Xie Y. ; Moaddel R. ; Sanghvi M. ; Dossou K. S. ; Kashuba A. D. ; Sandler R. S. ; Hawke R. L. Randomized Pharmacokinetic Crossover Study Comparing 2 Curcumin Preparations in Plasma and Rectal Tissue of Healthy Human Volunteers . J. Clin Pharmacol 2017 , 57 ( 2 ), 185 – 193 . 10.1002/jcph.806 . 27503249 PMC5233601

Pivari F. ; Mingione A. ; Piazzini G. ; Ceccarani C. ; Ottaviano E. ; Brasacchio C. ; Dei Cas M. ; Vischi M. ; Cozzolino M. G. ; Fogagnolo P. Curcumin Supplementation (Meriva((R))) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease . Nutrients 2022 , 14 ( 1 ), 231 10.3390/nu14010231 . 35011106 PMC8747135

Appendino G. ; Belcaro G. ; Cornelli U. ; Luzzi R. ; Togni S. ; Dugall M. ; Cesarone M. R. ; Feragalli B. ; Ippolito E. ; Errichi B. M. ; et al. Potential role of curcumin phytosome (Meriva) in controlling the evolution of diabetic microangiopathy. A pilot study . Panminerva Med. 2011 , 53 ( 3 Suppl 1 ), 43 – 49 . 22108476

Steigerwalt R. ; Nebbioso M. ; Appendino G. ; Belcaro G. ; Ciammaichella G. ; Cornelli U. ; Luzzi R. ; Togni S. ; Dugall M. ; Cesarone M. R. ; et al. Meriva(R), a lecithinized curcumin delivery system, in diabetic microangiopathy and retinopathy . Panminerva Med. 2012 , 54 ( 1 Suppl 4 ), 11 – 16 . 23241930

Donovan E. K. ; Kekes-Szabo S. ; Lin J. C. ; Massey R. L. ; Cobb J. D. ; Hodgin K. S. ; Ness T. J. ; Hangee-Bauer C. ; Younger J. W. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Curcuma longa), Boswellia (Boswellia serrata), and French Maritime Pine Bark (Pinus pinaster) . Int. J. Environ. Res. Public Health 2021 , 18 ( 5 ), 2468 10.3390/ijerph18052468 . 33802272 PMC7967595

Ferguson J. J. A. ; Stojanovski E. ; MacDonald-Wicks L. ; Garg M. L. Curcumin potentiates cholesterol-lowering effects of phytosterols in hypercholesterolaemic individuals. A randomised controlled trial . Metabolism 2018 , 82 , 22 – 35 . 10.1016/j.metabol.2017.12.009 . 29291429

Safarian H. ; Parizadeh S. M. R. ; Saberi-Karimain M. ; Darroudi S. ; Javandoost A. ; Mohammadi F. ; Moammeri M. ; Ferns G. A. ; Ghayour-Mobarhan M. ; Mohebati M. The Effect of Curcumin on Serum Copper and Zinc and Zn/Cu Ratio in Individuals with Metabolic Syndrome: A Double-Blind Clinical Trial . J. Diet Suppl 2019 , 16 ( 6 ), 625 – 634 . 10.1080/19390211.2018.1472711 . 30020812

Panahi Y. ; Kianpour P. ; Mohtashami R. ; Jafari R. ; Simental-Mendia L. E. ; Sahebkar A. Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial . J. Cardiovasc Pharmacol 2016 , 68 ( 3 ), 223 – 229 . 10.1097/FJC.0000000000000406 . 27124606

Panahi Y. ; Kianpour P. ; Mohtashami R. ; Jafari R. ; Simental-Mendia L. E. ; Sahebkar A. Efficacy and Safety of Phytosomal Curcumin in Non-Alcoholic Fatty Liver Disease: A Randomized Controlled Trial . Drug Res. (Stuttg) 2017 , 67 ( 4 ), 244 – 251 . 10.1055/s-0043-100019 . 28158893

Panahi Y. ; Kianpour P. ; Mohtashami R. ; Soflaei S. S. ; Sahebkar A. Efficacy of phospholipidated curcumin in nonalcoholic fatty liver disease: a clinical study . J. Asian Nat. Prod Res. 2019 , 21 ( 8 ), 798 – 805 . 10.1080/10286020.2018.1505873 . 30415581

Hariri M. ; Gholami A. ; Mirhafez S. R. ; Bidkhori M. ; Sahebkar A. A pilot study of the effect of curcumin on epigenetic changes and DNA damage among patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled, clinical trial . Complement Ther Med. 2020 , 51 , 102447 10.1016/j.ctim.2020.102447 . 32507446

Belcaro G. ; Cesarone M. R. ; Dugall M. ; Pellegrini L. ; Ledda A. ; Grossi M. G. ; Togni S. ; Appendino G. Product-evaluation registry of Meriva(R), a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis . Panminerva Med. 2010 , 52 ( 2 Suppl 1 ), 55 – 62 . 20657536

Belcaro G. ; Cesarone M. R. ; Dugall M. ; Pellegrini L. ; Ledda A. ; Grossi M. G. ; Togni S. ; Appendino G. Efficacy and safety of Meriva(R), a curcumin-phosphatidylcholine complex, during extended administration in osteoarthritis patients . Altern Med. Rev. 2010 , 15 ( 4 ), 337 – 344 . 21194249

Pastorelli D. ; Fabricio A. S. C. ; Giovanis P. ; D’Ippolito S. ; Fiduccia P. ; Solda C. ; Buda A. ; Sperti C. ; Bardini R. ; Da Dalt G. ; et al. Phytosome complex of curcumin as complementary therapy of advanced pancreatic cancer improves safety and efficacy of gemcitabine: Results of a prospective phase II trial . Pharmacol. Res. 2018 , 132 , 72 – 79 . 10.1016/j.phrs.2018.03.013 . 29614381

Ledda A. ; Belcaro G. ; Dugall M. ; Luzzi R. ; Scoccianti M. ; Togni S. ; Appendino G. ; Ciammaichella G. Meriva(R), a lecithinized curcumin delivery system, in the control of benign prostatic hyperplasia: a pilot, product evaluation registry study . Panminerva Med. 2012 , 54 ( 1 Suppl 4 ), 17 – 22 . 23241931

Antiga E. ; Bonciolini V. ; Volpi W. ; Del Bianco E. ; Caproni M. Oral Curcumin (Meriva) Is Effective as an Adjuvant Treatment and Is Able to Reduce IL-22 Serum Levels in Patients with Psoriasis Vulgaris . Biomed Res. Int. 2015 , 2015 , 283634 10.1155/2015/283634 . 26090395 PMC4450233

Thota R. N. ; Rosato J. I. ; Dias C. B. ; Burrows T. L. ; Martins R. N. ; Garg M. L. Dietary Supplementation with Curcumin Reduce Circulating Levels of Glycogen Synthase Kinase-3beta and Islet Amyloid Polypeptide in Adults with High Risk of Type 2 Diabetes and Alzheimer’s Disease . Nutrients 2020 , 12 ( 4 ), 1032 10.3390/nu12041032 . 32283762 PMC7230780

Panahi Y. ; Saadat A. ; Beiraghdar F. ; Sahebkar A. Adjuvant therapy with bioavailability-boosted curcuminoids suppresses systemic inflammation and improves quality of life in patients with solid tumors: a randomized double-blind placebo-controlled trial . Phytother Res. 2014 , 28 ( 10 ), 1461 – 1467 . 10.1002/ptr.5149 . 24648302

Belcaro G. ; Hosoi M. ; Pellegrini L. ; Appendino G. ; Ippolito E. ; Ricci A. ; Ledda A. ; Dugall M. ; Cesarone M. R. ; Maione C. ; et al. A controlled study of a lecithinized delivery system of curcumin (Meriva(R)) to alleviate the adverse effects of cancer treatment . Phytother Res. 2014 , 28 ( 3 ), 444 – 450 . 10.1002/ptr.5014 . 23775598

Chashmniam S. ; Mirhafez S. R. ; Dehabeh M. ; Hariri M. ; Azimi Nezhad M. ; Nobakht M. G. B. F. A pilot study of the effect of phospholipid curcumin on serum metabolomic profile in patients with non-alcoholic fatty liver disease: a randomized, double-blind, placebo-controlled trial . Eur. J. Clin Nutr 2019 , 73 ( 9 ), 1224 – 1235 . 10.1038/s41430-018-0386-5 . 30647436

Mirhafez S. R. ; Farimani A. R. ; Dehhabe M. ; Bidkhori M. ; Hariri M. ; Ghouchani B. F. ; Abdollahi F. Effect of Phytosomal Curcumin on Circulating Levels of Adiponectin and Leptin in Patients with Non-Alcoholic Fatty Liver Disease: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial . J. Gastrointestin Liver Dis 2019 , 28 , 183 – 189 . 10.15403/jgld-179 . 31204416

Mazzolani F. ; Togni S. ; Giacomelli L. ; Eggenhoffner R. ; Franceschi F. Oral administration of a curcumin-phospholipid formulation (Meriva(R)) for treatment of chronic diabetic macular edema: a pilot study . Eur. Rev. Med. Pharmacol Sci. 2018 , 22 ( 11 ), 3617 – 3625 . 10.26355/eurrev_201806_15189 . 29917217

Thota R. N. ; Dias C. B. ; Abbott K. A. ; Acharya S. H. ; Garg M. L. Curcumin alleviates postprandial glycaemic response in healthy subjects: A cross-over, randomized controlled study . Sci. Rep 2018 , 8 ( 1 ), 13679 10.1038/s41598-018-32032-x . 30209353 PMC6135827

Ferguson J. J. A. ; Wolska A. ; Remaley A. T. ; Stojanovski E. ; MacDonald-Wicks L. ; Garg M. L. Bread enriched with phytosterols with or without curcumin modulates lipoprotein profiles in hypercholesterolaemic individuals. A randomised controlled trial . Food Funct 2019 , 10 ( 5 ), 2515 – 2527 . 10.1039/C8FO02512F . 30990213

Briata I. M. ; Paleari L. ; Rutigliani M. ; Petrera M. ; Caviglia S. ; Romagnoli P. ; Libera M. D. ; Oppezzi M. ; Puntoni M. ; Siri G. ; et al. A Presurgical Study of Curcumin Combined with Anthocyanin Supplements in Patients with Colorectal Adenomatous Polyps . Int. J. Mol. Sci. 2021 , 22 ( 20 ), 11024 10.3390/ijms222011024 . 34681684 PMC8539981

Di Pierro F. ; Zacconi P. ; Bertuccioli A. ; Togni S. ; Eggenhoffner R. ; Giacomelli L. ; Scaltrini S. A naturally-inspired, curcumin-based lecithin formulation (Meriva(R) formulated as the finished product Algocur(R)) alleviates the osteo-muscular pain conditions in rugby players . Eur. Rev. Med. Pharmacol Sci. 2017 , 21 ( 21 ), 4935 – 4940 . 29164565

Wolf M. ; Klang V. ; Stojcic T. ; Fuchs C. ; Wolzt M. ; Valenta C. NLC versus nanoemulsions: Effect on physiological skin parameters during regular in vivo application and impact on drug penetration . Int. J. Pharm. 2018 , 549 ( 1–2 ), 343 – 351 . 10.1016/j.ijpharm.2018.08.007 . 30099212

Banerjee R. ; Pal P. ; Penmetsa A. ; Kathi P. ; Girish G. ; Goren I. ; Reddy D. N. Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study . J. Clin Gastroenterol 2021 , 55 ( 8 ), 702 – 708 . 10.1097/MCG.0000000000001416 . 32889959

Asawanonda P. ; Klahan S. O. Tetrahydrocurcuminoid cream plus targeted narrowband UVB phototherapy for vitiligo: a preliminary randomized controlled study . Photomed Laser Surg 2010 , 28 ( 5 ), 679 – 684 . 10.1089/pho.2009.2637 . 20961233

Dizaji B. F. ; Rivandi M. ; Javandoost A. ; Saberi Karimian M. ; Raei A. ; Sahebkar A. ; Ferns G. ; Mobarhan M. G. ; Pasdar A. Association of genetic polymorphisms of PON1 and CETP with the presence of metabolic syndrome; the effects of genotypes on their serum activity and concentrations . Egyptian Journal of Medical Human Genetics 2018 , 19 ( 1 ), 43 – 48 . 10.1016/j.ejmhg.2017.12.001 .

Ghazimoradi M. ; Saberi-Karimian M. ; Mohammadi F. ; Sahebkar A. ; Tavallaie S. ; Safarian H. ; Ferns G. A. ; Ghayour-Mobarhan M. ; Moohebati M. ; Esmaeili H. ; et al. The Effects of Curcumin and Curcumin-Phospholipid Complex on the Serum Pro-oxidant-Antioxidant Balance in Subjects with Metabolic Syndrome . Phytother Res. 2017 , 31 ( 11 ), 1715 – 1721 . 10.1002/ptr.5899 . 28840615

Mohammadi F. ; Ghazi-Moradi M. ; Ghayour-Mobarhan M. ; Esmaeili H. ; Moohebati M. ; Saberi-Karimian M. ; Safarian H. ; Tavallaie S. ; Ferns G. A. ; Sahebkar A. The Effects of Curcumin on Serum Heat Shock Protein 27 Antibody Titers in Patients with Metabolic Syndrome . J. Diet Suppl 2019 , 16 ( 5 ), 592 – 601 . 10.1080/19390211.2018.1472710 . 29958053

Saberi-Karimian M. ; Parizadeh S. M. R. ; Ghayour-Mobarhan M. ; Salahshooh M. M. ; Dizaji B. F. ; Safarian H. ; Javandoost A. ; Ferns G. A. ; Sahebkar A. ; Ahmadinejad M. Evaluation of the effects of curcumin in patients with metabolic syndrome . Comparative Clinical Pathology 2018 , 27 ( 3 ), 555 – 563 . 10.1007/s00580-017-2624-y .

Shirmohammadi L. ; Ghayour-Mobarhan M. ; Saberi-Karimian M. ; Iranshahi M. ; Tavallaie S. ; Emamian M. ; Sahebkar A. Effect of Curcumin on Serum Cathepsin D in Patients with Metabolic Syndrome . Cardiovasc Hematol Disord Drug Targets 2020 , 20 ( 2 ), 116 – 121 . 10.2174/1871529X19666190919110652 . 31538907

Saberi-Karimian M. ; Ghazizadeh H. ; Mohammadzadeh E. ; Ferns G. A. ; Ghayour-Mobarhan M. ; Sahebkar A. Does curcumin have an effect on sleep duration in metabolic syndrome patients? . Avicenna J. Phytomed 2021 , 11 ( 2 ), 190 – 198 . 33907677 PMC8051315

Bisht S. ; Feldmann G. ; Soni S. ; Ravi R. ; Karikar C. ; Maitra A. ; Maitra A. Polymeric nanoparticle-encapsulated curcumin (″nanocurcumin″): a novel strategy for human cancer therapy . J. Nanobiotechnology 2007 , 5 , 3 10.1186/1477-3155-5-3 . 17439648 PMC1868037

Duan J. ; Zhang Y. ; Han S. ; Chen Y. ; Li B. ; Liao M. ; Chen W. ; Deng X. ; Zhao J. ; Huang B. Synthesis and in vitro/in vivo anti-cancer evaluation of curcumin-loaded chitosan/poly(butyl cyanoacrylate) nanoparticles . Int. J. Pharm. 2010 , 400 ( 1–2 ), 211 – 220 . 10.1016/j.ijpharm.2010.08.033 . 20813175

Nair K. L. ; Thulasidasan A. K. ; Deepa G. ; Anto R. J. ; Kumar G. S. Purely aqueous PLGA nanoparticulate formulations of curcumin exhibit enhanced anticancer activity with dependence on the combination of the carrier . Int. J. Pharm. 2012 , 425 ( 1–2 ), 44 – 52 . 10.1016/j.ijpharm.2012.01.003 . 22266528

Mohanty C. ; Sahoo S. K. The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation . Biomaterials 2010 , 31 ( 25 ), 6597 – 6611 . 10.1016/j.biomaterials.2010.04.062 . 20553984

Bertrand N. ; Wu J. ; Xu X. ; Kamaly N. ; Farokhzad O. C. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology . Adv. Drug Deliv Rev. 2014 , 66 , 2 – 25 . 10.1016/j.addr.2013.11.009 . 24270007 PMC4219254

Rahman M. M. ; Islam M. R. ; Akash S. ; Harun-Or-Rashid M. ; Ray T. K. ; Rahaman M. S. ; Islam M. ; Anika F. ; Hosain M. K. ; Aovi F. I. ; et al. Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance . Biomed Pharmacother 2022 , 153 , 113305 10.1016/j.biopha.2022.113305 . 35717779

Kamaly N. ; Yameen B. ; Wu J. ; Farokhzad O. C. Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release . Chem. Rev. 2016 , 116 ( 4 ), 2602 – 2663 . 10.1021/acs.chemrev.5b00346 . 26854975 PMC5509216

Gosangari S. L. ; Watkin K. L. Effect of preparation techniques on the properties of curcumin liposomes: characterization of size, release and cytotoxicity on a squamous oral carcinoma cell line . Pharm. Dev Technol. 2012 , 17 ( 1 ), 103 – 109 . 10.3109/10837450.2010.522583 . 21091385

Lin H. Y. ; Thomas J. L. ; Chen H. W. ; Shen C. M. ; Yang W. J. ; Lee M. H. In vitro suppression of oral squamous cell carcinoma growth by ultrasound-mediated delivery of curcumin microemulsions . Int. J. Nanomedicine 2012 , 7 , 941 – 951 . 10.2147/IJN.S28510 . 22393291 PMC3289448

Ahmadi M. ; Agah E. ; Nafissi S. ; Jaafari M. R. ; Harirchian M. H. ; Sarraf P. ; Faghihi-Kashani S. ; Hosseini S. J. ; Ghoreishi A. ; Aghamollaii V. ; et al. Safety and Efficacy of Nanocurcumin as Add-On Therapy to Riluzole in Patients With Amyotrophic Lateral Sclerosis: A Pilot Randomized Clinical Trial . Neurotherapeutics 2018 , 15 ( 2 ), 430 – 438 . 10.1007/s13311-018-0606-7 . 29352425 PMC5935637

Hajialilo M. ; Dolati S. ; Abdolmohammadi-Vahid S. ; Ahmadi M. ; Kamrani A. ; Eghbal-Fard S. ; Ghassembaglou A. ; Valizadeh A. ; Shenas M. H. M. ; Aghebati-Maleki L. ; et al. Nanocurcumin: A novel strategy in treating ankylosing spondylitis by modulating Th17 cells frequency and function . J. Cell Biochem 2019 , 120 , 12027 10.1002/jcb.28488 . 30805973

Mogharrabi M. ; Rahimi H. R. ; Hasanzadeh S. ; Dastani M. ; Kazemi-Oskuee R. ; Akhlaghi S. ; Soukhtanloo M. The effects of nanomicelle of curcumin on the matrix metalloproteinase (MMP-2, 9) activity and expression in patients with coronary artery disease (CAD): A randomized controlled clinical trial . ARYA Atheroscler 2020 , 16 ( 3 ), 136 – 145 . 10.22122/arya.v16i3.1938 . 33447259 PMC7778509

Ahmadi R. ; Salari S. ; Sharifi M. D. ; Reihani H. ; Rostamiani M. B. ; Behmadi M. ; Taherzadeh Z. ; Eslami S. ; Rezayat S. M. ; Jaafari M. R. ; et al. Oral nano-curcumin formulation efficacy in the management of mild to moderate outpatient COVID-19: A randomized triple-blind placebo-controlled clinical trial . Food Sci. Nutr 2021 , 9 ( 8 ), 4068 – 4075 . 10.1002/fsn3.2226 . 34401058 PMC8358331

Honarkar Shafie E. ; Taheri F. ; Alijani N. ; Okhovvat A. R. ; Goudarzi R. ; Borumandnia N. ; Aghaghazvini L. ; Rezayat S. M. ; Jamalimoghadamsiahkali S. ; Hosseinzadeh-Attar M. J. Effect of nanocurcumin supplementation on the severity of symptoms and length of hospital stay in patients with COVID-19: A randomized double-blind placebo-controlled trial . Phytother Res. 2022 , 36 ( 2 ), 1013 – 1022 . 10.1002/ptr.7374 . 35023260

Delavarian Z. ; Pakfetrat A. ; Ghazi A. ; Jaafari M. R. ; Homaei Shandiz F. ; Dalirsani Z. ; Mohammadpour A. H. ; Rahimi H. R. Oral administration of nanomicelle curcumin in the prevention of radiotherapy-induced mucositis in head and neck cancers . Spec Care Dentist 2019 , 39 ( 2 ), 166 – 172 . 10.1111/scd.12358 . 30761565

Saadipoor A. ; Razzaghdoust A. ; Simforoosh N. ; Mahdavi A. ; Bakhshandeh M. ; Moghadam M. ; Abdollahi H. ; Mofid B. Randomized, double-blind, placebo-controlled phase II trial of nanocurcumin in prostate cancer patients undergoing radiotherapy . Phytother Res. 2019 , 33 ( 2 ), 370 – 378 . 10.1002/ptr.6230 . 30427093

Javadi M. ; Khadem Haghighian H. ; Goodarzy S. ; Abbasi M. ; Nassiri-Asl M. Effect of curcumin nanomicelle on the clinical symptoms of patients with rheumatoid arthritis: A randomized, double-blind, controlled trial . Int. J. Rheum Dis 2019 , 22 ( 10 ), 1857 – 1862 . 10.1111/1756-185X.13688 . 31482684

Atabaki M. ; Shariati-Sarabi Z. ; Tavakkol-Afshari J. ; Mohammadi M. Significant immunomodulatory properties of curcumin in patients with osteoarthritis; a successful clinical trial in Iran . Int. Immunopharmacol 2020 , 85 , 106607 10.1016/j.intimp.2020.106607 . 32540725

Naeini F. ; Tutunchi H. ; Razmi H. ; Mahmoodpoor A. ; Vajdi M. ; Sefidmooye Azar P. ; Najifipour F. ; Tarighat-Esfanjani A. ; Karimi A. Does nano-curcumin supplementation improve hematological indices in critically ill patients with sepsis? A randomized controlled clinical trial . J. Food Biochem 2022 , 46 ( 5 ), e14093 10.1111/jfbc.14093 . 35150143

Farhadi M. ; Bakhshandeh M. ; Shafiei B. ; Mahmoudzadeh A. ; Hosseinimehr S. J. The radioprotective effects of nano-curcumin against genotoxicity induced by iodine-131 in patients with differentiated thyroid carcinoma (DTC) by micronucleus assay . International Journal of Cancer Management 2018 , 10.5812/ijcm.14193 .

Alizadeh F. ; Javadi M. ; Karami A. A. ; Gholaminejad F. ; Kavianpour M. ; Haghighian H. K. Curcumin nanomicelle improves semen parameters, oxidative stress, inflammatory biomarkers, and reproductive hormones in infertile men: A randomized clinical trial . Phytother Res. 2018 , 32 ( 3 ), 514 – 521 . 10.1002/ptr.5998 . 29193350

Bateni Z. ; Rahimi H. R. ; Hedayati M. ; Afsharian S. ; Goudarzi R. ; Sohrab G. The effects of nano-curcumin supplementation on glycemic control, blood pressure, lipid profile, and insulin resistance in patients with the metabolic syndrome: A randomized, double-blind clinical trial . Phytother Res. 2021 , 35 ( 7 ), 3945 – 3953 . 10.1002/ptr.7109 . 33851448

Ghodsi H. ; Rahimi H. R. ; Aghili S. M. ; Saberi A. ; Shoeibi A. Evaluation of curcumin as add-on therapy in patients with Parkinson’s disease: A pilot randomized, triple-blind, placebo-controlled trial . Clin Neurol Neurosurg 2022 , 218 , 107300 10.1016/j.clineuro.2022.107300 . 35636380

Dolati S. ; Aghebati-Maleki L. ; Ahmadi M. ; Marofi F. ; Babaloo Z. ; Ayramloo H. ; Jafarisavari Z. ; Oskouei H. ; Afkham A. ; Younesi V. ; et al. Nanocurcumin restores aberrant miRNA expression profile in multiple sclerosis, randomized, double-blind, placebo-controlled trial . J. Cell Physiol 2018 , 233 ( 7 ), 5222 – 5230 . 10.1002/jcp.26301 . 29194612

Hosseininasab M. ; Zarghami M. ; Mazhari S. ; Salehifar E. ; Moosazadeh M. ; Fariborzifar A. ; Babaeirad S. ; Hendouei N. Nanocurcumin as an Add-on to Antipsychotic Drugs for Treatment of Negative Symptoms in Patients With Chronic Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Study . J. Clin Psychopharmacol 2021 , 41 ( 1 ), 25 – 30 . 10.1097/JCP.0000000000001324 . 33347019

Maulina T. ; Diana H. ; Cahyanto A. ; Amaliya A. The efficacy of curcumin in managing acute inflammation pain on the post-surgical removal of impacted third molars patients: A randomised controlled trial . J. Oral Rehabil 2018 , 45 ( 9 ), 677 – 683 . 10.1111/joor.12679 . 29908031

Masoodi M. ; Mahdiabadi M. A. ; Mokhtare M. ; Agah S. ; Kashani A. H. F. ; Rezadoost A. M. ; Sabzikarian M. ; Talebi A. ; Sahebkar A. The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients’ self-reported well-being: A randomized double-blind controlled trial . J. Cell Biochem 2018 , 119 ( 11 ), 9552 – 9559 . 10.1002/jcb.27273 . 30132960

Atabaki M. ; Shariati-Sarabi Z. ; Tavakkol-Afshari J. ; Taghipour A. ; Jafari M. R. ; Nikpoor A. R. ; Mohammadi M. Curcumin as an effective suppressor of miRNA expression in patients with knee osteoarthritis . Avicenna J. Phytomed 2022 , 12 ( 4 ), 346 – 356 . 10.22038/AJP.2021.19380 . 35782767 PMC9121260

Abbasian S. ; Soltani-Zangbar M. S. ; Khabbazi A. ; Farzaneh R. ; Malek Mahdavi A. ; Motavalli R. ; Hajialilo M. ; Yousefi M. Nanocurcumin supplementation ameliorates Behcet’s disease by modulating regulatory T cells: A randomized, double-blind, placebo-controlled trial . Int. Immunopharmacol 2021 , 101 , 108237 10.1016/j.intimp.2021.108237 . 34653732

Valizadeh H. ; Abdolmohammadi-Vahid S. ; Danshina S. ; Ziya Gencer M. ; Ammari A. ; Sadeghi A. ; Roshangar L. ; Aslani S. ; Esmaeilzadeh A. ; Ghaebi M. ; et al. Nano-curcumin therapy, a promising method in modulating inflammatory cytokines in COVID-19 patients . Int. Immunopharmacol 2020 , 89 , 107088 10.1016/j.intimp.2020.107088 . 33129099 PMC7574843

Tahmasebi S. ; Saeed B. Q. ; Temirgalieva E. ; Yumashev A. V. ; El-Esawi M. A. ; Navashenaq J. G. ; Valizadeh H. ; Sadeghi A. ; Aslani S. ; Yousefi M. ; et al. Nanocurcumin improves Treg cell responses in patients with mild and severe SARS-CoV2 . Life Sci. 2021 , 276 , 119437 10.1016/j.lfs.2021.119437 . 33789145 PMC8005319

Hassaniazad M. ; Eftekhar E. ; Inchehsablagh B. R. ; Kamali H. ; Tousi A. ; Jaafari M. R. ; Rafat M. ; Fathalipour M. ; Nikoofal-Sahlabadi S. ; Gouklani H. ; et al. A triple-blind, placebo-controlled, randomized clinical trial to evaluate the effect of curcumin-containing nanomicelles on cellular immune responses subtypes and clinical outcome in COVID-19 patients . Phytother Res. 2021 , 35 ( 11 ), 6417 – 6427 . 10.1002/ptr.7294 . 34541720 PMC8661812

Tahmasebi S. ; El-Esawi M. A. ; Mahmoud Z. H. ; Timoshin A. ; Valizadeh H. ; Roshangar L. ; Varshoch M. ; Vaez A. ; Aslani S. ; Navashenaq J. G. ; et al. Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients . J. Cell Physiol 2021 , 236 ( 7 ), 5325 – 5338 . 10.1002/jcp.30233 . 33372280

Asadirad A. ; Nashibi R. ; Khodadadi A. ; Ghadiri A. A. ; Sadeghi M. ; Aminian A. ; Dehnavi S. Antiinflammatory potential of nano-curcumin as an alternative therapeutic agent for the treatment of mild-to-moderate hospitalized COVID-19 patients in a placebo-controlled clinical trial . Phytother Res. 2022 , 36 ( 2 ), 1023 – 1031 . 10.1002/ptr.7375 . 35040210

Saber-Moghaddam N. ; Salari S. ; Hejazi S. ; Amini M. ; Taherzadeh Z. ; Eslami S. ; Rezayat S. M. ; Jaafari M. R. ; Elyasi S. Oral nano-curcumin formulation efficacy in management of mild to moderate hospitalized coronavirus disease-19 patients: An open label nonrandomized clinical trial . Phytother Res. 2021 , 35 , 2616 10.1002/ptr.7004 . 33389761

Karimi A. ; Mahmoodpoor A. ; Kooshki F. ; Niazkar H. R. ; Shoorei H. ; Tarighat-Esfanjani A. Effects of nanocurcumin on inflammatory factors and clinical outcomes in critically ill patients with sepsis: A pilot randomized clinical trial . European Journal of Integrative Medicine 2020 , 36 , 101122 10.1016/j.eujim.2020.101122 .

Karimi A. ; Naeini F. ; Niazkar H. R. ; Tutunchi H. ; Musazadeh V. ; Mahmoodpoor A. ; Asghariazar V. ; Mobasseri M. ; Tarighat-Esfanjani A. Nano-curcumin supplementation in critically ill patients with sepsis: a randomized clinical trial investigating the inflammatory biomarkers, oxidative stress indices, endothelial function, clinical outcomes and nutritional status . Food Funct 2022 , 13 ( 12 ), 6596 – 6612 . 10.1039/D1FO03746C . 35621073

Sandoughdaran S. ; Razzaghdoust A. ; Tabibi A. ; Basiri A. ; Simforoosh N. ; Mofid B. Randomized, Double-blind Pilot Study of Nanocurcumin in Bladder Cancer Patients Receiving Induction Chemotherapy . Urol J. 2020 , 18 ( 3 ), 295 – 300 . 10.22037/uj.v0i0.5719 . 32350847

Kia S. J. ; Basirat M. ; Mortezaie T. ; Moosavi M. S. Comparison of oral Nano-Curcumin with oral prednisolone on oral lichen planus: a randomized double-blinded clinical trial . BMC Complement Med. Ther 2020 , 20 ( 1 ), 328 10.1186/s12906-020-03128-7 . 33129289 PMC7603687

Mokhtari M. ; Razzaghi R. ; Momen-Heravi M. The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial . Phytother Res. 2021 , 35 ( 4 ), 2099 – 2107 . 10.1002/ptr.6957 . 33200488

Shafabakhsh R. ; Asemi Z. ; Reiner Z. ; Soleimani A. ; Aghadavod E. ; Bahmani F. The Effects of Nano-curcumin on Metabolic Status in Patients With Diabetes on Hemodialysis, a Randomized, Double Blind, Placebo-controlled Trial . Iran J. Kidney Dis 2020 , 14 ( 4 ), 290 – 299 . 32655024

Zamani S. K. ; Rezagholizadeh D. M. Effect of eight-week curcumin supplementation with endurance training on glycemic indexes in middle age women with type 2 diabetes in Iran, A preliminary study . Diabetes Metab Syndr 2021 , 15 ( 3 ), 963 – 967 . 10.1016/j.dsx.2021.04.002 . 33946029

Asadi S. ; Gholami M. S. ; Siassi F. ; Qorbani M. ; Sotoudeh G. Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial . Phytother Res. 2020 , 34 ( 4 ), 896 – 903 . 10.1002/ptr.6571 . 31788880

Asadi S. ; Gholami M. S. ; Siassi F. ; Qorbani M. ; Khamoshian K. ; Sotoudeh G. Nano curcumin supplementation reduced the severity of diabetic sensorimotor polyneuropathy in patients with type 2 diabetes mellitus: A randomized double-blind placebo- controlled clinical trial . Complement Ther Med. 2019 , 43 , 253 – 260 . 10.1016/j.ctim.2019.02.014 . 30935539

Bateni Z. ; Behrouz V. ; Rahimi H. R. ; Hedayati M. ; Afsharian S. ; Sohrab G. Effects of nano-curcumin supplementation on oxidative stress, systemic inflammation, adiponectin, and NF-κB in patients with metabolic syndrome: A randomized, double-blind clinical trial . Journal of Herbal Medicine 2022 , 31 , 100531 10.1016/j.hermed.2021.100531 .

Jazayeri-Tehrani S. A. ; Rezayat S. M. ; Mansouri S. ; Qorbani M. ; Alavian S. M. ; Daneshi-Maskooni M. ; Hosseinzadeh-Attar M. J. Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial . Nutr Metab (Lond) 2019 , 16 , 8 10.1186/s12986-019-0331-1 . 30705687 PMC6348610

Sedighiyan M. ; Abdolahi M. ; Jafari E. ; Vahabi Z. ; Sohrabi Athar S. ; Hadavi S. ; Narimani Zamanabadi M. ; Yekaninejad M. S. ; Djalali M. The effects of nano-curcumin supplementation on adipokines levels in obese and overweight patients with migraine: a double blind clinical trial study . BMC Res. Notes 2022 , 15 ( 1 ), 189 10.1186/s13104-022-06074-4 . 35606882 PMC9125853

Parohan M. ; Sarraf P. ; Javanbakht M. H. ; Foroushani A. R. ; Ranji-Burachaloo S. ; Djalali M. The synergistic effects of nano-curcumin and coenzyme Q10 supplementation in migraine prophylaxis: a randomized, placebo-controlled, double-blind trial . Nutr Neurosci 2021 , 24 ( 4 ), 317 – 326 . 10.1080/1028415X.2019.1627770 . 31241007

Abdolahi M. ; Karimi E. ; Sarraf P. ; Tafakhori A. ; Siri G. ; Salehinia F. ; Sedighiyan M. ; Asanjarani B. ; Badeli M. ; Abdollahi H. ; et al. The omega-3 and Nano-curcumin effects on vascular cell adhesion molecule (VCAM) in episodic migraine patients: a randomized clinical trial . BMC Res. Notes 2021 , 14 ( 1 ), 283 10.1186/s13104-021-05700-x . 34301320 PMC8305494

Honarvar N. M. ; Soveid N. ; Abdolahi M. ; Djalali M. ; Hatami M. ; Karzar N. H. Anti-Neuroinflammatory Properties of n-3 Fatty Acids and Nano- Curcumin on Migraine Patients from Cellular to Clinical Insight: A Randomized, Double-Blind and Placebo-Controlled Trial . Endocr Metab Immune Disord Drug Targets 2021 , 21 ( 2 ), 365 – 373 . 10.2174/1871530320666200729144430 . 32727335

Dolati S. ; Ahmadi M. ; Rikhtegar R. ; Babaloo Z. ; Ayromlou H. ; Aghebati-Maleki L. ; Nouri M. ; Yousefi M. Changes in Th17 cells function after nanocurcumin use to treat multiple sclerosis . Int. Immunopharmacol 2018 , 61 , 74 – 81 . 10.1016/j.intimp.2018.05.018 . 29852475

Dolati S. ; Babaloo Z. ; Ayromlou H. ; Ahmadi M. ; Rikhtegar R. ; Rostamzadeh D. ; Roshangar L. ; Nouri M. ; Mehdizadeh A. ; Younesi V. ; et al. Nanocurcumin improves regulatory T-cell frequency and function in patients with multiple sclerosis . J. Neuroimmunol 2019 , 327 , 15 – 21 . 10.1016/j.jneuroim.2019.01.007 . 30683426

Malekzadeh M. ; Kia S. J. ; Mashaei L. ; Moosavi M. S. Oral nano-curcumin on gingival inflammation in patients with gingivitis and mild periodontitis . Clin Exp Dent Res. 2021 , 7 ( 1 ), 78 – 84 . 10.1002/cre2.330 . 32954688 PMC7853903

Kia S. J. ; Basirat M. ; Saedi H. S. ; Arab S. A. Effects of nanomicelle curcumin capsules on prevention and treatment of oral mucosits in patients under chemotherapy with or without head and neck radiotherapy: a randomized clinical trial . BMC Complement Med. Ther 2021 , 21 ( 1 ), 232 10.1186/s12906-021-03400-4 . 34521398 PMC8442420

Bakhshi M. ; Gholami S. ; Mahboubi A. ; Jaafari M. R. ; Namdari M. Combination Therapy with 1% Nanocurcumin Gel and 0.1% Triamcinolone Acetonide Mouth Rinse for Oral Lichen Planus: A Randomized Double-Blind Placebo Controlled Clinical Trial . Dermatol Res. Pract 2020 , 2020 , 4298193 10.1155/2020/4298193 . 32518558 PMC7256737

Bakhshi M. ; Mahboubi A. ; Jaafari M. R. ; Ebrahimi F. ; Tofangchiha M. ; Alizadeh A. Comparative Efficacy of 1% Curcumin Nanomicelle Gel and 2% Curcumin Gel for Treatment of Recurrent Aphthous Stomatitis: A Double-Blind Randomized Clinical Trial . J. Evid Based Dent Pract 2022 , 22 ( 2 ), 101708 10.1016/j.jebdp.2022.101708 . 35718440

Osali A. Aerobic exercise and nano-curcumin supplementation improve inflammation in elderly females with metabolic syndrome . Diabetol Metab Syndr 2020 , 12 , 26 10.1186/s13098-020-00532-4 . 32256716 PMC7106798

Talakesh T. ; Tabatabaee N. ; Atoof F. ; Aliasgharzadeh A. ; Sarvizade M. ; Farhood B. ; Najafi M. Effect of Nano-Curcumin on Radiotherapy-Induced Skin Reaction in Breast Cancer Patients: A Randomized, Triple-Blind, Placebo-Controlled Trial . Curr. Radiopharm 2022 , 15 , 332 10.2174/1874471015666220623104316 . 35747962

Djalali M. ; Djalali M. ; Abdolahi M. ; Mohammadi H. ; Heidari H. ; Hosseini S. ; Sadeghizadeh M. The Effect of Nano-Curcumin Supplementation on Pentraxin 3 Gene Expression and Serum Level in Migraine Patients . Rep. Biochem Mol. Biol. 2020 , 9 ( 1 ), 1 – 7 . 10.29252/rbmb.9.1.1 . 32821745 PMC7424412

Abdolahi M. ; Sarraf P. ; Javanbakht M. H. ; Honarvar N. M. ; Hatami M. ; Soveyd N. ; Tafakhori A. ; Sedighiyan M. ; Djalali M. ; Jafarieh A. ; et al. A Novel Combination of omega-3 Fatty Acids and Nano-Curcumin Modulates Interleukin-6 Gene Expression and High Sensitivity C-reactive Protein Serum Levels in Patients with Migraine: A Randomized Clinical Trial Study . CNS Neurol Disord Drug Targets 2018 , 17 ( 6 ), 430 – 438 . 10.2174/1871527317666180625101643 . 29938621

Djalali M. ; Abdolahi M. ; Hosseini R. ; Miraghajani M. ; Mohammadi H. ; Djalali M. The effects of nano-curcumin supplementation on Th1/Th17 balance in migraine patients: A randomized controlled clinical trial . Complement Ther Clin Pract 2020 , 41 , 101256 10.1016/j.ctcp.2020.101256 . 33147541

Nivetha B. ; Rahmathunisha A. ; Lokeshwari K. ; Kumaresan A. ; Nikkitha S. K. ; Yeseshivi L. ; Janani R. Efficacy of nanocurcumin with application of iontophoresis on inflammatory arthritis patients . Research Journal of Pharmacy and Technology 2022 , 15 ( 2 ), 825 – 829 . 10.52711/0974-360X.2022.00137 .

Soveyd N. ; Abdolahi M. ; Djalali M. ; Hatami M. ; Tafakhori A. ; Sarraf P. ; Honarvar N. M. The Combined Effects of omega −3 Fatty Acids and Nano-Curcumin Supplementation on Intercellular Adhesion Molecule-1 (ICAM-1) Gene Expression and Serum Levels in Migraine Patients . CNS Neurol Disord Drug Targets 2018 , 16 ( 10 ), 1120 – 1126 . 10.2174/1871527317666171213154749 . 29237386

Abdolahi M. ; Tafakhori A. ; Togha M. ; Okhovat A. A. ; Siassi F. ; Eshraghian M. R. ; Sedighiyan M. ; Djalali M. ; Mohammadzadeh Honarvar N. ; Djalali M. The synergistic effects of omega-3 fatty acids and nano-curcumin supplementation on tumor necrosis factor (TNF)-alpha gene expression and serum level in migraine patients . Immunogenetics 2017 , 69 ( 6 ), 371 – 378 . 10.1007/s00251-017-0992-8 . 28478481

Abdolahi M. ; Jafarieh A. ; Sarraf P. ; Sedighiyan M. ; Yousefi A. ; Tafakhori A. ; Abdollahi H. ; Salehinia F. ; Djalali M. The Neuromodulatory Effects of omega-3 Fatty Acids and Nano-Curcumin on the COX-2/ iNOS Network in Migraines: A Clinical Trial Study from Gene Expression to Clinical Symptoms . Endocr Metab Immune Disord Drug Targets 2019 , 19 ( 6 ), 874 – 884 . 10.2174/1871530319666190212170140 . 30760195

Bilia A. R. ; Bergonzi M. C. ; Isacchi B. ; Antiga E. ; Caproni M. Curcumin nanoparticles potentiate therapeutic effectiveness of acitrein in moderate-to-severe psoriasis patients and control serum cholesterol levels . J. Pharm. Pharmacol 2018 , 70 ( 7 ), 919 – 928 . 10.1111/jphp.12910 . 29600580

Farshbaf-Khalili A. ; Farajnia S. ; Pourzeinali S. ; Shakouri S. K. ; Salehi-Pourmehr H. The effect of nanomicelle curcumin supplementation and Nigella sativa oil on the expression level of miRNA-21, miRNA-422a, and miRNA-503 gene in postmenopausal women with low bone mass density: A randomized, triple-blind, placebo-controlled clinical trial with factorial design . Phytother Res. 2021 , 35 ( 11 ), 6216 – 6227 . 10.1002/ptr.7259 . 34496087

Shah S. ; Rath H. ; Sharma G. ; Senapati S. N. ; Mishra E. Effectiveness of curcumin mouthwash on radiation-induced oral mucositis among head and neck cancer patients: A triple-blind, pilot randomised controlled trial . Indian J. Dent Res. 2020 , 31 ( 5 ), 718 – 727 . 10.4103/ijdr.IJDR_822_18 . 33433509

Moradi Kelardeh B. ; Rahmati-Ahmadabad S. ; Farzanegi P. ; Helalizadeh M. ; Azarbayjani M. A. Effects of non-linear resistance training and curcumin supplementation on the liver biochemical markers levels and structure in older women with non-alcoholic fatty liver disease . J. Bodyw Mov Ther 2020 , 24 ( 3 ), 154 – 160 . 10.1016/j.jbmt.2020.02.021 . 32825982

Guru S. R. ; Reddy K. A. ; Rao R. J. ; Padmanabhan S. ; Guru R. ; Srinivasa T. S. Comparative evaluation of 2% turmeric extract with nanocarrier and 1% chlorhexidine gel as an adjunct to scaling and root planing in patients with chronic periodontitis: A pilot randomized controlled clinical trial . J. Indian Soc. Periodontol 2020 , 24 ( 3 ), 244 – 252 . 10.4103/jisp.jisp_207_19 . 32773975 PMC7307465

Perez-Pacheco C. G. ; Fernandes N. A. R. ; Primo F. L. ; Tedesco A. C. ; Bellile E. ; Retamal-Valdes B. ; Feres M. ; Guimaraes-Stabili M. R. ; Rossa C. Jr. Local application of curcumin-loaded nanoparticles as an adjunct to scaling and root planing in periodontitis: Randomized, placebo-controlled, double-blind split-mouth clinical trial . Clin Oral Investig 2021 , 25 ( 5 ), 3217 – 3227 . 10.1007/s00784-020-03652-3 . 33125518

Small G. W. ; Siddarth P. ; Li Z. ; Miller K. J. ; Ercoli L. ; Emerson N. D. ; Martinez J. ; Wong K. P. ; Liu J. ; Merrill D. A. ; et al. Memory and Brain Amyloid and Tau Effects of a Bioavailable Form of Curcumin in Non-Demented Adults: A Double-Blind, Placebo-Controlled 18-Month Trial . Am. J. Geriatr Psychiatry 2018 , 26 ( 3 ), 266 – 277 . 10.1016/j.jagp.2017.10.010 . 29246725

Ross S. M. Curcuma longa (Theracumin(R)): A Bioavailable Form of Curcumin and Its Cognitive Benefits . Holist Nurs Pract 2018 , 32 ( 4 ), 217 – 220 . 10.1097/HNP.0000000000000281 . 29894377

Sasaki H. ; Sunagawa Y. ; Takahashi K. ; Imaizumi A. ; Fukuda H. ; Hashimoto T. ; Wada H. ; Katanasaka Y. ; Kakeya H. ; Fujita M. ; et al. Innovative preparation of curcumin for improved oral bioavailability . Biol. Pharm. Bull. 2011 , 34 ( 5 ), 660 – 665 . 10.1248/bpb.34.660 . 21532153

Kanai M. ; Imaizumi A. ; Otsuka Y. ; Sasaki H. ; Hashiguchi M. ; Tsujiko K. ; Matsumoto S. ; Ishiguro H. ; Chiba T. Dose-escalation and pharmacokinetic study of nanoparticle curcumin, a potential anticancer agent with improved bioavailability, in healthy human volunteers . Cancer Chemother Pharmacol 2012 , 69 ( 1 ), 65 – 70 . 10.1007/s00280-011-1673-1 . 21603867

Tanabe Y. ; Maeda S. ; Akazawa N. ; Zempo-Miyaki A. ; Choi Y. ; Ra S. G. ; Imaizumi A. ; Otsuka Y. ; Nosaka K. Attenuation of indirect markers of eccentric exercise-induced muscle damage by curcumin . Eur. J. Appl. Physiol 2015 , 115 ( 9 ), 1949 – 1957 . 10.1007/s00421-015-3170-4 . 25921600 PMC4536282

Kanai M. ; Otsuka Y. ; Otsuka K. ; Sato M. ; Nishimura T. ; Mori Y. ; Kawaguchi M. ; Hatano E. ; Kodama Y. ; Matsumoto S. ; et al. A phase I study investigating the safety and pharmacokinetics of highly bioavailable curcumin (Theracurmin) in cancer patients . Cancer Chemother Pharmacol 2013 , 71 ( 6 ), 1521 – 1530 . 10.1007/s00280-013-2151-8 . 23543271

Morimoto T. ; Sunagawa Y. ; Katanasaka Y. ; Hirano S. ; Namiki M. ; Watanabe Y. ; Suzuki H. ; Doi O. ; Suzuki K. ; Yamauchi M. ; et al. Drinkable preparation of Theracurmin exhibits high absorption efficiency--a single-dose, double-blind, 4-way crossover study . Biol. Pharm. Bull. 2013 , 36 ( 11 ), 1708 – 1714 . 10.1248/bpb.b13-00150 . 24189415

Tanabe Y. ; Chino K. ; Sagayama H. ; Lee H. J. ; Ozawa H. ; Maeda S. ; Takahashi H. Effective Timing of Curcumin Ingestion to Attenuate Eccentric Exercise-Induced Muscle Soreness in Men . J. Nutr Sci. Vitaminol (Tokyo) 2019 , 65 ( 1 ), 82 – 89 . 10.3177/jnsv.65.82 . 30814417

Tanabe Y. ; Chino K. ; Ohnishi T. ; Ozawa H. ; Sagayama H. ; Maeda S. ; Takahashi H. Effects of oral curcumin ingested before or after eccentric exercise on markers of muscle damage and inflammation . Scand J. Med. Sci. Sports 2019 , 29 ( 4 ), 524 – 534 . 10.1111/sms.13373 . 30566760

Sugawara J. ; Akazawa N. ; Miyaki A. ; Choi Y. ; Tanabe Y. ; Imai T. ; Maeda S. Effect of endurance exercise training and curcumin intake on central arterial hemodynamics in postmenopausal women: pilot study . Am. J. Hypertens 2012 , 25 ( 6 ), 651 – 656 . 10.1038/ajh.2012.24 . 22421908

Sugimoto K. ; Ikeya K. ; Bamba S. ; Andoh A. ; Yamasaki H. ; Mitsuyama K. ; Nasuno M. ; Tanaka H. ; Matsuura A. ; Kato M. ; et al. Highly Bioavailable Curcumin Derivative Ameliorates Crohn’s Disease Symptoms: A Randomized, Double-Blind, Multicenter Study . J. Crohns Colitis 2020 , 14 ( 12 ), 1693 – 1701 . 10.1093/ecco-jcc/jjaa097 . 32412598

Vafadar-Afshar G. ; Rasmi Y. ; Yaghmaei P. ; Khadem-Ansari M. H. ; Makhdoomi K. ; Rasouli J. The effects of nanocurcumin supplementation on inflammation in hemodialysis patients: A randomized controlled trial . Hemodial Int. 2021 , 25 ( 2 ), 232 – 239 . 10.1111/hdi.12911 . 33559343

Nakagawa Y. ; Mori K. ; Yamada S. ; Mukai S. ; Hirose A. ; Nakamura R. The Oral Administration of Highly-Bioavailable Curcumin for One Year Has Clinical and Chondro-Protective Effects: A Randomized, Double-Blinded, Placebo-Controlled Prospective Study . Arthrosc Sports Med. Rehabil 2022 , 4 ( 2 ), e393 – e402 . 10.1016/j.asmr.2021.10.016 . 35494290 PMC9042777

Funamoto M. ; Sunagawa Y. ; Katanasaka Y. ; Miyazaki Y. ; Imaizumi A. ; Kakeya H. ; Yamakage H. ; Satoh-Asahara N. ; Komiyama M. ; Wada H. ; et al. Highly absorptive curcumin reduces serum atherosclerotic low-density lipoprotein levels in patients with mild COPD . Int. J. Chron Obstruct Pulmon Dis 2016 , 11 , 2029 – 2034 . 10.2147/COPD.S104490 . 27616885 PMC5008445

Funamoto M. ; Shimizu K. ; Sunagawa Y. ; Katanasaka Y. ; Miyazaki Y. ; Kakeya H. ; Yamakage H. ; Satoh-Asahara N. ; Wada H. ; Hasegawa K. ; et al. Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus . J. Diabetes Res. 2019 , 2019 , 8208237 10.1155/2019/8208237 . 31871950 PMC6906884

Banik K. ; Khatoon E. ; Hegde M. ; Thakur K. K. ; Puppala E. R. ; Naidu V. G. M. ; Kunnumakkara A. B. A novel bioavailable curcumin-galactomannan complex modulates the genes responsible for the development of chronic diseases in mice: A RNA sequence analysis . Life Sci. 2021 , 287 , 120074 10.1016/j.lfs.2021.120074 . 34687757

Krishnakumar I. ; Maliakel A. ; Gopakumar G. ; Kumar D. ; Maliakel B. ; Kuttan R. Improved blood–brain-barrier permeability and tissue distribution following the oral administration of a food-grade formulation of curcumin with fenugreek fibre . Journal of functional foods 2015 , 14 , 215 – 225 . 10.1016/j.jff.2015.01.049 .

Sunagawa Y. ; Miyazaki Y. ; Funamoto M. ; Shimizu K. ; Shimizu S. ; Nurmila S. ; Katanasaka Y. ; Ito M. ; Ogawa T. ; Ozawa-Umeta H. ; et al. A novel amorphous preparation improved curcumin bioavailability in healthy volunteers: A single-dose, double-blind, two-way crossover study . Journal of Functional Foods 2021 , 81 , 104443 10.1016/j.jff.2021.104443 .

Khanna A. ; Das S. S. ; Smina T. P. ; Thomas J. V. ; Kunnumakkara A. B. ; Maliakel B. ; Krishnakumar I. M. ; Mohanan R. Curcumagalactomannoside/Glucosamine Combination Improved Joint Health Among Osteoarthritic Subjects as Compared to Chondroitin Sulfate/Glucosamine: Double-Blinded, Randomized Controlled Study . J. Altern Complement Med. 2020 , 26 ( 10 ), 945 – 955 . 10.1089/acm.2020.0128 . 32678677

Pandaran Sudheeran S. ; Jacob D. ; Natinga Mulakal J. ; Gopinathan Nair G. ; Maliakel A. ; Maliakel B. ; Kuttan R. ; Im K. Safety, Tolerance, and Enhanced Efficacy of a Bioavailable Formulation of Curcumin With Fenugreek Dietary Fiber on Occupational Stress: A Randomized, Double-Blind, Placebo-Controlled Pilot Study . J. Clin Psychopharmacol 2016 , 36 ( 3 ), 236 – 243 . 10.1097/JCP.0000000000000508 . 27043120

Campbell M. S. ; Ouyang A. ; I M. K. ; Charnigo R. J. ; Westgate P. M. ; Fleenor B. S. Influence of enhanced bioavailable curcumin on obesity-associated cardiovascular disease risk factors and arterial function: A double-blinded, randomized, controlled trial . Nutrition 2019 , 62 , 135 – 139 . 10.1016/j.nut.2019.01.002 . 30889454

Thomas J. V. ; Smina T. P. ; Khanna A. ; Kunnumakkara A. B. ; Maliakel B. ; Mohanan R. ; Krishnakumar I. M. Influence of a low-dose supplementation of curcumagalactomannoside complex (CurQfen) in knee osteoarthritis: A randomized, open-labeled, active-controlled clinical trial . Phytother Res. 2021 , 35 ( 3 ), 1443 – 1455 . 10.1002/ptr.6907 . 33210408

Khanna A. ; Das S. S. ; Kannan R. ; Swick A. G. ; Matthewman C. ; Maliakel B. ; Ittiyavirah S. P. ; Krishnakumar I. M. The effects of oral administration of curcumin-galactomannan complex on brain waves are consistent with brain penetration: a randomized, double-blinded, placebo-controlled pilot study . Nutr Neurosci 2022 , 25 ( 6 ), 1240 – 1249 . 10.1080/1028415X.2020.1853410 . 33295851

Kishimoto A. ; Imaizumi A. ; Wada H. ; Yamakage H. ; Satoh-Asahara N. ; Hashimoto T. ; Hasegawa K. Newly Developed Highly Bioavailable Curcumin Formulation, curcuRouge(TM), Reduces Neutrophil/Lymphocyte Ratio in the Elderly: A Double-Blind, Placebo-Controlled Clinical Trial . J. Nutr Sci. Vitaminol (Tokyo) 2021 , 67 ( 4 ), 249 – 252 . 10.3177/jnsv.67.249 . 34471000

Kothaplly S. ; Alukapally S. ; Nagula N. ; Maddela R. Superior Bioavailability of a Novel Curcumin Formulation in Healthy Humans Under Fasting Conditions . Adv. Ther 2022 , 39 ( 5 ), 2128 – 2138 . 10.1007/s12325-022-02081-w . 35294738 PMC9056459

Cox K. H. ; Pipingas A. ; Scholey A. B. Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population . J. Psychopharmacol 2015 , 29 ( 5 ), 642 – 651 . 10.1177/0269881114552744 . 25277322

Cox K. H. M. ; White D. J. ; Pipingas A. ; Poorun K. ; Scholey A. Further Evidence of Benefits to Mood and Working Memory from Lipidated Curcumin in Healthy Older People: A 12-Week, Double-Blind, Placebo-Controlled, Partial Replication Study . Nutrients 2020 , 12 ( 6 ), 1678 10.3390/nu12061678 . 32512782 PMC7352411

Santos-Parker J. R. ; Strahler T. R. ; Bassett C. J. ; Bispham N. Z. ; Chonchol M. B. ; Seals D. R. Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress . Aging (Albany NY) 2017 , 9 ( 1 ), 187 – 208 . 10.18632/aging.101149 . 28070018 PMC5310664

DiSilvestro R. A. ; Joseph E. ; Zhao S. ; Bomser J. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people . Nutr J. 2012 , 11 , 79 10.1186/1475-2891-11-79 . 23013352 PMC3518252

Kuszewski J. C. ; Howe P. R. C. ; Wong R. H. X. Evaluation of Cognitive Performance following Fish-Oil and Curcumin Supplementation in Middle-Aged and Older Adults with Overweight or Obesity . J. Nutr. 2020 , 150 ( 12 ), 3190 – 3199 . 10.1093/jn/nxaa299 . 33097947

Kuszewski J. C. ; Wong R. H. X. ; Howe P. R. C. Fish oil supplementation reduces osteoarthritis-specific pain in older adults with overweight/obesity . Rheumatol Adv. Pract 2020 , 4 ( 2 ), rkaa036 10.1093/rap/rkaa036 . 32968708 PMC7494084

Kuszewski J. C. ; Wong R. H. X. ; Wood L. G. ; Howe P. R. C. Effects of fish oil and curcumin supplementation on cerebrovascular function in older adults: A randomized controlled trial . Nutr Metab Cardiovasc Dis 2020 , 30 ( 4 ), 625 – 633 . 10.1016/j.numecd.2019.12.010 . 32127335

Hazarey V. K. ; Sakrikar A. R. ; Ganvir S. M. Efficacy of curcumin in the treatment for oral submucous fibrosis - A randomized clinical trial . J. Oral Maxillofac Pathol 2015 , 19 ( 2 ), 145 – 152 . 10.4103/0973-029X.164524 . 26604488 PMC4611920

Gupte P. A. ; Giramkar S. A. ; Harke S. M. ; Kulkarni S. K. ; Deshmukh A. P. ; Hingorani L. L. ; Mahajan M. P. ; Bhalerao S. S. Evaluation of the efficacy and safety of Capsule Longvida((R)) Optimized Curcumin (solid lipid curcumin particles) in knee osteoarthritis: a pilot clinical study . J. Inflamm Res. 2019 , 12 , 145 – 152 . 10.2147/JIR.S205390 . 31239749 PMC6559772

Ngolab J. ; Donohue M. ; Belsha A. ; Salazar J. ; Cohen P. ; Jaiswal S. ; Tan V. ; Gessert D. ; Korouri S. ; Aggarwal N. T. ; et al. Feasibility study for detection of retinal amyloid in clinical trials: The Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4) trial . Alzheimers Dement (Amst) 2021 , 13 ( 1 ), e12199 10.1002/dad2.12199 . 34430703 PMC8369843